

Optimising experimental research in respiratory diseases

Citation for published version (APA):

Bonnaud, P., Fabre, A., Frossard, N., Guignabert, C., Inman, M., Kuebler, W. M., Maes, T., Shi, W., Stampfli, M., Uhlig, S., White, E., Witzenrath, M., Bellaye, P.-S., Crestani, B., Eickelberg, O., Fehrenbach, H., Guenther, A., Jenkins, G., Joos, G., ... Kolb, M. (2018). Optimising experimental research in respiratory diseases: an ERS statement. *European Respiratory Journal*, 51(5), Article 1702133. <https://doi.org/10.1183/13993003.02133-2017>

Document status and date:

Published: 01/05/2018

DOI:

[10.1183/13993003.02133-2017](https://doi.org/10.1183/13993003.02133-2017)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy



If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.



Optimising experimental research in respiratory diseases: an ERS statement

Philippe Bonniaud^{1,2,3}, Aurélie Fabre⁴, Nelly Frossard^{5,6,7},
Christophe Guignabert ^{8,9}, Mark Inman¹⁰, Wolfgang M. Kuebler¹¹,
Tania Maes¹², Wei Shi^{13,14}, Martin Stampfli^{10,15}, Stefan Uhlig¹⁶, Eric White¹⁷,
Martin Witzernath¹⁸, Pierre-Simon Bellaye¹⁹, Bruno Crestani^{20,21,22},
Oliver Eickelberg ²³, Heinz Fehrenbach^{24,25}, Andreas Guenther²⁶,
Gisli Jenkins²⁷, Guy Joos²⁸, Antoine Magnan²⁹, Bernard Maitre³⁰,
Ulrich A. Maus³¹, Petra Reinhold³², Juanita H.J. Vernooij³³, Luca Richeldi³⁴ and
Martin Kolb¹⁰

 @ERSpublications
This document summarises the benefits and limitations of current lung disease models and how they can be improved <http://ow.ly/SLFT30jEoCf>

Cite this article as: Bonniaud P, Fabre A, Frossard N, *et al.* Optimising experimental research in respiratory diseases: an ERS statement. *Eur Respir J* 2018; 51: 1702133 [<https://doi.org/10.1183/13993003.02133-2017>].

ABSTRACT Experimental models are critical for the understanding of lung health and disease and are indispensable for drug development. However, the pathogenetic and clinical relevance of the models is often unclear. Further, the use of animals in biomedical research is controversial from an ethical perspective.

The objective of this task force was to issue a statement with research recommendations about lung disease models by facilitating in-depth discussions between respiratory scientists, and to provide an overview of the literature on the available models. Focus was put on their specific benefits and limitations. This will result in more efficient use of resources and greater reduction in the numbers of animals employed, thereby enhancing the ethical standards and translational capacity of experimental research.

The task force statement addresses general issues of experimental research (ethics, species, sex, age, *ex vivo* and *in vitro* models, gene editing). The statement also includes research recommendations on modelling asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, lung infections, acute lung injury and pulmonary hypertension.

The task force stressed the importance of using multiple models to strengthen validity of results, the need to increase the availability of human tissues and the importance of standard operating procedures and data quality.

This article has supplementary material available from erj.ersjournals.com

This document was endorsed by the by the ERS Science Council and Executive Committee in April 2018.

Received: Oct 16 2017 | Accepted after revision: April 02 2018

Copyright ©ERS 2018

Affiliations: ¹Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Bourgogne, Dijon, France. ²Faculté de Médecine et Pharmacie, Université de Bourgogne-Franche Comté, Dijon, France. ³INSERM U866, Dijon, France. ⁴Dept of Histopathology, St Vincent's University Hospital, UCD School of Medicine, University College Dublin, Dublin, Ireland. ⁵Laboratoire d'Innovation Thérapeutique, Université de Strasbourg, Strasbourg, France. ⁶CNRS UMR 7200, Faculté de Pharmacie, Illkirch, France. ⁷Labex MEDALIS, Université de Strasbourg, Strasbourg, France. ⁸INSERM UMR_S 999, Le Plessis-Robinson, France. ⁹Université Paris-Sud and Université Paris-Saclay, Le Kremlin-Bicêtre, France. ¹⁰Dept of Medicine, Firestone Institute for Respiratory Health at St Joseph's Health Care MDCL 4011, McMaster University, Hamilton, ON, Canada. ¹¹Institute of Physiology, Charité – Universitätsmedizin Berlin, Berlin, Germany. ¹²Dept of Respiratory Medicine, Laboratory for Translational Research in Obstructive Pulmonary Diseases, Ghent University Hospital, Ghent, Belgium. ¹³Developmental Biology and Regenerative Medicine Program, The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA, USA. ¹⁴Dept of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. ¹⁵Dept of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University. ¹⁶Institute of Pharmacology and Toxicology, RWTH Aachen University, Aachen, Germany. ¹⁷Division of Pulmonary and Critical Care Medicine, Dept of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA. ¹⁸Dept of Infectious Diseases and Respiratory Medicine And Division of Pulmonary Inflammation, Charité – Universitätsmedizin Berlin, Berlin, Germany. ¹⁹Département de Médecine nucléaire, Plateforme d'imagerie préclinique, Centre George-François Leclerc (CGFL), Dijon, France. ²⁰Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, DHU FIRE, Service de Pneumologie A, Paris, France. ²¹INSERM UMR 1152, Paris, France. ²²Université Paris Diderot, Paris, France. ²³Division of Pulmonary Sciences and Critical Care Medicine, Dept of Medicine, University of Colorado, Aurora, CO, USA. ²⁴Priority Area Asthma & Allergy, Research Center Borstel, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany. ²⁵Member of the Leibniz Research Alliance Health Technologies. ²⁶Justus-Liebig-University Giessen, University Hospital Giessen, Agaplesion Lung Clinic Waldhof-Elgershausen, German Center for Lung Research, Giessen, Germany. ²⁷Nottingham Biomedical Research Centre, Respiratory Research Unit, City Campus, University of Nottingham, Nottingham, UK. ²⁸Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium. ²⁹Institut du thorax, CHU de Nantes, Université de Nantes, Nantes, France. ³⁰Hôpital H Mondor, AP-HP, Centre Hospitalier Intercommunal de Créteil, Service de Pneumologie et de Pathologie Professionnelle, DHU A-TVb, Université Paris Est – Créteil, Créteil, France. ³¹Hannover School of Medicine, Division of Experimental Pneumology, Hannover, Germany. ³²Institute of Molecular Pathogenesis at the 'Friedrich-Loeffler-Institut' (Federal Research Institute for Animal Health), Jena, Germany. ³³Dept of Respiratory Medicine, Maastricht University Medical Center+ (MUMC+), AZ Maastricht, The Netherlands. ³⁴UOC Pneumologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario "A. Gemelli", Rome, Italy.

Correspondence: Martin Kolb, McMaster University, Dept of Respiratory Medicine, Pathology and Molecular Medicine, 50 Charlton Ave East, Hamilton, ON L8N 4A6, Canada. E-mail: kolbm@mcmaster.ca

Introduction

Animal models, organs and cell cultures are often used to assist in understanding human biology. These models are critical for the exploration of putative mechanisms in health and pathogenesis in disease, and are indispensable for the development of novel drugs. However, the pathogenetic and clinical relevance of disease models and their translational potential are often uncertain. The modelling of chronic diseases is particularly challenging. Further, the use of animals for medical research has become an important point of discussion from an ethical and political perspective [1]. Substantial efforts have been undertaken by the scientific community including the development and application of the “3Rs principles” (Refinement, Reduction, Replacement) that were introduced 60 years ago to establish the highest standards for humane experimentation on animals [2].

Numerous options for modelling specific diseases in lung research exist. Traditional and established models, as well as increasingly sophisticated newer approaches, are available, stressing the need to critically choose the best model for the research question under investigation [3]. For the foreseeable future, animal models will remain an important tool for exploring the pathogenesis of pulmonary diseases and to validate new targets, treatments and mechanisms of action of potential agents for clinical use. Appropriate and meaningful readouts and standardised end-points must be employed to obtain relevant and generalisable results. Incorrect application, or interpretation, of models has resulted in failure to translate preclinical findings to human diseases, a major challenge in all areas of medicine [4–6].

The European Respiratory Society (ERS) task force “Optimising experimental research in respiratory diseases” was established to create a comprehensive document that provides statements based on literature review and research recommendations on the best possible use of models in major areas of respiratory medicine. The task force addressed a number of general questions that are of relevance to all areas of experimental medicine. These include animal ethics, choice of species, sex and age of laboratory animals, the role of *ex vivo* and *in vitro* models, the benefits and limitations of typical outcome measurements, and the principles of gene manipulation. The task force then focused on modelling specific respiratory diseases, namely asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, lung infections, acute lung injury (ALI) and pulmonary hypertension. The task force acknowledges that this report covers *in vivo*

models more than *ex vivo*, which results from the original aim of the task force and the resulting literature search, the current scientific discussions on the validity of animal models, and the fact that animal models are still an important tool for exploring the pathogenesis of pulmonary diseases.

We believe that this statement focusing on animal models is likely to contribute to refinement and reduction of the use of animal models.

Methods

This ERS task force was initiated in 2014 after an ERS research seminar held in Paris (France) in October 2013. The task force was composed of a multinational, multidisciplinary group of 25 clinical and research experts. Potential participants with appropriate expertise were identified by the chairs (M. Kolb, P. Bonniaud). Broad representation of countries from Europe and North America was sought. Members were vetted for potential conflicts of interest according to the policies of the ERS. The following aims were stated prior to the inaugural meeting: 1) to issue a statement document with research recommendations about lung disease models by facilitating in depth discussions between respiratory scientists from different pulmonary subspecialties; and 2) to provide better knowledge of the available models, especially their specific benefits and limitations, that will result in more efficient use of resources, reduction in the numbers of animals in research and that will enhance the ethical standards of experimental research.

Face-to-face meetings were held during the ERS International Congresses 2014–2016. The task force members were committed to creating a document with scientific rigour and transparency of the methods used to evaluate available information. The task force statement goes beyond a typical state of the art review by providing a comprehensive and unbiased summary and evaluation of the literature.

The task force statement is organised into: 1) general issues (animal ethics, species, sex and age, *ex vivo* and *in vitro* models, outcome measurements, principles of gene editing) and 2) specific respiratory diseases (asthma, COPD, pulmonary fibrosis, lung infections, ALI and pulmonary hypertension). Lung cancer was not discussed as the panel members felt that addressing the complexity of modelling cancer needs more specific expertise and is best discussed in the context of lung cancers at large. For similar reasons, neonatal and developmental models were not discussed. Task force members were assigned to focus on one or more sections, based on clinical and scientific expertise and group leaders were appointed for each section (A. Fabre, C. Guignabert, E. White, N. Frossard, M. Inman, W. Shi, W.M. Kuebler, M. Witzernath, M. Stampfli, S. Uhlig). Groups identified four to six key and focused questions relevant for the topic (see headers in the following sections).

Two ERS methodologists (T. Tonia, D. Rigau) had the methodological overview. The task force group leaders coordinated regular exchange by telecommunication between group members. The task force members reviewed current knowledge and new scientific advances through identifying relevant individual studies and reviews from a systematic search in MEDLINE database through PubMed (last search June 2017; however, task force members also tracked any relevant citation appeared beyond this date). The search was limited to English literature with no date limitations. This document was created by combining a systematic literature review with the research expertise of the task force members.

After a 1-day face-to-face meeting at ERS headquarters in Lausanne, Switzerland, the document was drafted. This document was critically reviewed by two senior clinician scientists with a recognised expertise in methodology in clinical research (L. Richeldi, G. Jenkins) and a junior scientist (P-S. Bellaye). All task force members unanimously agreed to its content.

The supplementary material provides detailed information on: 1) anaesthesia and euthanasia of rodents; 2) pre-analytical conditions of tissues/cell harvesting/collection/storage; 3) large animal models for respiratory diseases; 4) COPD, including clinically relevant subgroup of COPD, environmental factors and exacerbations; 5) infection/pneumonia; and 6) all the references numbered in the 14 tables.

Animal ethics

Ethical principles in animal research (“the 3Rs”)

Research aimed at improving health of humans at the expense of animals has always been a topic of ethical debate. What is not debated is that whenever such research occurs, oversight is needed to ensure that exploitation of animals is minimised. Most countries mandate an extensive set of rules and enforce them by animal ethics committees at all research centres within that country or union [2]. The basic principles are focused on: 1) *Reduction*, or more accurately minimisation, of the numbers of animals, 2) *Replacement*, wherever possible, of animal research with *in vitro* or *in silico* modelling, or ethical research with human participants and 3) *Refinement* of research methods in an attempt to reduce the suffering of the animal.

The ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines are intended to improve the design, analysis and reporting of research using animals and thus maximising information published and minimising unnecessary studies [7].

Ethical oversight

A recent systematic review of mouse-based research in tuberculosis shows a promising trend where more studies report oversight by ethics boards and indicate the adoption of humane end-points [8]. There also remain studies that fail to report elements of ethical oversight, and most studies still fail to report on methods of euthanasia [8].

Misinterpretation of findings

There is a growing concern with animal research regarding the extent to which it informs about human disease. Scientists argue whether a study has translational impact [9] while the public debates whether animal-based medical research is a “complete mistake” [10]. Clearly, many of those animal studies that do not directly lead to new treatments do, nonetheless, provide valuable insights for future treatments. There is an important conceptual difference between studies aiming at determining basic mechanisms of injury *versus* mechanisms of resolution, particularly related to a therapeutic intervention (figure 1). While there may be overlap between these in acute disease (*e.g.* treatment of infection with antibiotics results in resolution of inflammation), there may be no overlap whatsoever in chronic disease (*e.g.* blocking of a mediator that promotes deposition of fibrogenic matrix may fail to reverse established fibrotic matrix). Despite the clear distinction between injury and resolution, animal researchers often hesitate to acknowledge the limitations of their model and incorrectly present new insights in disease pathogenesis as novel therapeutic options.

Negative results

Publication of negative results is a major problem for scientists as there is low appetite for journals to publish them. At the current time there is little to guide editors as to whether the reasons for a negative result is due to methodological failings or whether the results represents a “true” negative outcome. However, if negative results were publishable, it would also reduce redundancy and is in line with the 3R approach [11]. One way to achieve this would be to pre-register studies and peer review these protocols,




FIGURE 1 Human disease involves a period of pathogenesis, resulting in a diseased state. The clinical reality of many diseases, especially chronic diseases is that treatments that reverse pathogenesis are not available. To address this failing, researchers develop models, where perturbations reproduce features of the disease, with the goal that this will aid in the development of treatments to reverse these features. A failing in the logical extension of this reasoning is that interventional research in these models is usually applied to healthy animals, or animals early in the timing of the perturbation (1), as opposed to “diseased” animals (2) which actually model the human patient.

thereby confirming that the method was appropriate for the questions asked and that the negative result was correct.

Statistics

Statistical methods are essential for calculating the degree of confidence, the validity of experimental results and generalisability of the findings to other species and systems. In many papers, the lack of information detailing the statistical methods makes it difficult to judge whether or not the statistical analyses are correct and if the data had been efficiently extracted and analysed [12]. Again, this would be aided by the pre-registration of studies, which would require the inclusion of a statistical analysis plan.

Interaction with human research ethics

While the ethical principles of animal research are covered in national guidelines, care needs to be taken in cases where this research overlaps with human research ethics. An example is the use of chimeric models in which elements of human tissue (often immune cells) are introduced into a mouse host.

Recommendations for experimental research in respiratory diseases

- Clearly describe the rationale for the choice of the model, the identity of the ethical oversight committee, and the criteria/methods used to proceed to euthanasia.
- Ensure that both animal and human ethical oversight is granted and documented when required.
- Clearly state whether the interventional approach is aimed at uncovering mechanisms of pathogenesis or possible resolution (especially in models of chronic disease).
- Not claim that uncovering mechanisms of pathogenesis may lead to a new treatment unless this is warranted.
- Consider publication of negative results and encourage journals to accept negative results for publication.
- Ensure that appropriate analytical expertise is used to assess method repeatability and quality of analysis.
- Ensure that appropriate and stringent statistical analysis is used and provide detailed statistical methods in publications.
- Consider pre-registration of animal studies (as occurs with clinical trials and systematic reviews).
- Animal studies should be reported in accordance with the ARRIVE guidelines.

Structure, function and imaging

Imaging techniques become highly sophisticated and many of them are applicable both in humans and in animal research. Imaging bears a singular potential to advance our understanding of respiratory diseases by providing unique structural and functional information. With this in mind, the task force addressed five specific questions.

How can we utilise imaging to obtain better in-depth understanding of disease processes?

Multidimensional molecular/functional and anatomical/structural imaging provides multilevel information from the molecular to organismic scale [13, 14]. *Anatomical imaging* is used to measure parameters related to structure, such as lung volume and tissue density. *Molecular or functional imaging* using radiotracers, fluorescent probes or contrast agents can visualise biological and physiological processes such as metabolism, inflammation, permeability, ventilation, gas exchange, perfusion, infection or mucociliary clearance (table 1).

What functions do we need to model, and how well do we do this in vivo and in vitro?

Given the abundance of functions pertinent to lung health and disease [15], the task force focused on key physiological functions at the organ, and general functions at the cellular level (table 2).

What does structure teach us about disease processes, and how can we assess it?

Structural analysis allows determining how structure relates to function, how injury alters structure, and to assess tissue repair in response to pharmacological interventions [16]. Structural analyses may be invasive or noninvasive, can be performed *in vivo*, *ex vivo*, *in vitro* or *in silico*. The analyses complement functional and molecular studies, and translate cellular pathways into disease- and patient-relevant pathologies [17]. Whenever possible, quantitative approaches should be implemented [17].

TABLE 1 Different imaging principles and modalities applied for the study of structure and function in lung disease processes

Imaging principle	Modality	Application	References
Nuclear imaging	Positron emission tomography (PET)	Use of radiotracers to locate and track biological events, <i>e.g.</i> metabolism (fludeoxyglucose)	[S1]
	Single photon emission computed tomography (SPECT)	Use of radiotracers and detection by gamma-rays with the ability to yield true three-dimensional information	[S2]
Radiographic imaging	X-ray	Including use of contrast agents, microfocal radiographic imaging and synchrotron-based imaging	[S3]
	Magnetic resonance imaging (MRI)	Including use of contrast agents such as perfluorocarbons or hyperpolarised gases	[S4, S5]
Fluorescence imaging	Computer tomography (CT)	Including use of contrast agents	[S2]
	Microscopy	Localise and quantify cellular and subcellular processes by use of fluorescent probes/proteins/dyes	[S6]
	Whole body imager	Temporo-spatial expression of fluorescent proteins, trafficking of fluorescently labelled cells	[S7]
Bioluminescence imaging	Microscopy, whole body imager	Enzymatic generation of visible light emitted typically from reporter genes	[S8]
Interferometry imaging	Optical coherence tomography (OCT)	Including time and frequency domain OCT, Doppler OCT	[S9, S10]

For references listed in the table please refer to the supplementary material.

How does the biological context determine the outcome of in situ versus in vitro disease models?

Cellular responses to physiological and pathological stimuli depend on the microenvironment in which these stimuli act on target cells, *i.e.* they are highly context dependent [18, 19]. Cells within an intact anatomical and physiological environment constantly receive (and, reciprocally, send) *contextual cues* that will determine their phenotype, and their response to physiological or injurious stimuli. When the nature, composition, or extent of these cues changes, cells undergo phenotypic shifts. This (typically biomechanical or biochemical) effect on biological processes has to be considered when interpreting models of cellular responses (table 3).

Which technical advancements are required to better interrogate models mechanistically?

Assessment of disease processes over time is the norm in the clinical scenario. In contrast, assessment of disease severity in animals is often a terminal measurement using composites of histological, biochemical, biomechanical, and physiological end-points. While these analyses provide multiscale insight into the disease from the level of single molecules to intact organisms, they provide only a brief snapshot within the continuum between health, disease and recovery. Technical advancements are required that provide better temporal resolution of biological processes, their functional effects and the

TABLE 2 A review from the literature of key functions modelled in experimental lung research *in vivo* and *in vitro*

Function	<i>In vivo</i> modelling	<i>In vitro</i> modelling	References
Lung and airway mechanics	Spontaneous breathing, mechanical ventilation	Cell stretch devices (table 3), precision cut lung slices (for airway dynamics), isolated airways	[S11–S13]
	Any <i>in vivo</i> model	Isolated perfused lungs, shear stress models (table 3), isolated vessel segments or rings	[S14, S15]
Oxygenation	Any <i>in vivo</i> model	No <i>in vitro</i> models	
	Any <i>in vivo</i> model	Permeability and translocation assays, lung-on-a-chip model, isolated perfused lungs	[S16–S18]
Barrier function			
Tissue remodelling	Animal models of chronic lung disease	Proliferation, hypertrophy, apoptosis, and migration assays; differentiation/de-differentiation/transdifferentiation; matrix deposition and remodelling; juxtacrine/autocrine/paracrine/endocrine signalling	[S19–S21]
Immunity, inflammation, defence	Models of infection, sterile inflammation, and autoimmunity	Adhesion and migration; juxtacrine/autocrine/paracrine/endocrine signalling; phagocytosis	[S22, S23]

For references listed in the table please refer to the supplementary material.

TABLE 3 A review from the literature of the different context-dependent dimensions that will determine cellular responses *in vivo*, and how they may be modelled *in vitro* or *ex vivo*

Context	Dimension	Systems used to model dimension <i>ex vivo</i> or <i>in vitro</i>	References
Mechanical	Shear stress	Flow chambers, microfluidics, cone-and-plate system, lung-on-a-chip	[S24]
	Cyclic stretch	Cell and tissue stretchers	[S25]
	Pulsatility	Oscillatory flow or shear, collapsible systems	[S26]
	Substrate stiffness	Hydrogels, PDMS membranes	[S27]
Biochemical	Autocrine	Monoculture	[S28]
	Paracrine	Co-culture, conditioned media	[S29]
	Endocrine	Conditioned media	[S30]
Cell contacts	Juxtacrine	Wounding assays, co-culture	[S31]
Location and geometry	Three-dimensional structure	Three-dimensional organoids, matrigels, scaffolds, <i>ex vivo</i> models	[S32]
	Compartmentalisation	Transwell co-cultures, de- and re-cellularised lungs, lung-on-a-chip	[S16, S33]

For references listed in the table please refer to the supplementary material.

underlying mechanisms. Given its unique abilities for parallel spatial and temporal image resolution, real-time visualisation could prove ideal for these requirements [20]. However, imaging of disease processes in the intact lung still has technical challenges (table 4) common to all imaging modalities. These have to be resolved to unfold the full potential for structural, functional and mechanistic analyses of imaging techniques.

Task force statements

- State of the art imaging modalities provide unique multidimensional and multiscale insights into structural and functional features of the intact and diseased lung that are ideally suited to allow for new mechanistic discoveries and development and testing of novel therapeutics.
- The mechanical, biochemical, and anatomical context play an important role as critical determinants of biological/physiological responses that need to be appropriately mimicked *in vitro* or *ex vivo* depending on the respective research question.

Recommendations for experimental research in respiratory diseases

- Include quantitative image analysis in addition to representative images (illustration *versus* quantification).

In vivo versus *ex vivo* models

Animal models play an important role in the investigation of health and disease (figure 2). Rodents have emerged as a reliable research species due to size, life span, reproductive affluence and defined genetic background. Further, the opportunity for gene editing and the availability of sophisticated molecular and

TABLE 4 Current limitations to noninvasive, temporo-spatial imaging of pulmonary structure, function and underlying mechanisms in lung disease, as well as current approaches and aspired solutions to overcome them

Limitation	Current approach	Aspired solution	References
Motion artefacts	Suction manifolds, triggered data acquisition	Ultra-fast autofocus and three-dimension landmark tracking	[S34, S35]
Noninvasiveness	Radiographic techniques for macroscopic noninvasive imaging, electrical impedance tomography, endoscopic confocal imaging	Noninvasive transthoracic microscopy	[S13, S36, S37]
Tissue penetration	Two- and multi-photon microscopy; confocal microscopy; optical coherence tomography (OCT) imaging	Refraction/reflection free or compensated imaging	[S38–S40]
Contrast agents and functional tracer dyes	Injection of contrast agents, loading of fluorescent dyes	Adoptive transfer of labelled cells, inducible cell-specific expression of functional markers and dyes	[S41]

For references listed in the table please refer to the supplementary material.




FIGURE 2 Limitations and advantages of animal models.

genetic tools facilitate studies in a cost-efficient way [21]. However, the challenge for disease models is their validity to reflect major hallmarks of human disorders, in the context of chronic progressive and irreversible changes. In some instances, the aetiological factors and natural history of the disease are unknown (e.g. idiopathic pulmonary fibrosis (IPF), idiopathic pulmonary arterial hypertension), while in others a molecular signature is lacking (e.g. acute respiratory distress syndrome (ARDS)); in both cases modelling becomes more difficult. Further, differences in physiology and pharmacology between animals and man have to be considered [22]. For intervention studies, the routes of drug administration also influence the interpretation of the findings.

The limitations of animal models (figure 2) provide the rationale for expanded use of alternative models for experimental research, particularly human *ex vivo* tissue and cell cultures and three-dimensional reconstructed tissues [23]. For the epithelium, an evolving area is the use of *in vitro* systems to visualise the cellular mechanisms that drive epithelial tissue development, to study the genetic regulation of cell behaviour in epithelial tissues and to evaluate the role of micro-environmental factors in normal development and disease. More recently, high precision cut lung slices (PCLS) have received increased interest in lung research [24]. PCLS are generated from explanted human lungs obtained during lung transplantation. They represent biomaterials from end-stage lungs from well selected patients without major comorbidities. Some of the limitations of PCLS are that the impact of circulating cellular and humoral factors and the effects of breathing and an air–liquid interface cannot be studied. On the other hand, PCLS reflect the complex cellular composition and the matrix effects of a diseased human lung, and biological diversity underlying differential treatment response in patients may well be studied in PCLS from different patients.

How is a model selected?

The American National Research Council Committee on Animal Models for Research and Aging defines an animal model as “... one in which normative biology or behaviour can be studied, or in

TABLE 5 Large animal models of non-infectious and infectious respiratory diseases

	Comparable spontaneous disease in animals (natural model)	Large animal models	Reference
Non-infectious respiratory disease in humans			
Allergic asthma	Feline asthma	Cats, dogs, sheep	Cat [S69–S72], dog [S73–S75], sheep [S76]
Non-allergic asthma	Equine asthma, heaves	Horses	[S77–S79]
“Ski-asthma”/ exercise-induced airway inflammation	Racing sled dogs	Dogs	[S80, S81]
Chronic obstructive pulmonary disease (COPD)	Equine COB (chronic obstructive bronchitis) (RAO; recurrent airway obstruction)	Horses	[S82, S83]
Pulmonary hypertension	High altitude pulmonary hypertension in cattle (brisket disease)	Calves	[S84–S89]
Respiratory distress syndrome (newborns)	Many species	Preterm lamb, preterm pig	[S90, S91]
Acute respiratory distress syndrome (ARDS)		Pigs, sheep	[S92, S93]
Cystic fibrosis		Genetically modified pigs (disruption of the CFTR gene)	[S94–S97]
Sleep disordered breathing	English bulldog		[S98]
Sleep apnoea	Obese miniature pigs		[S99]
Respiratory infection in humans			
Respiratory syncytial virus (RSV)	Bovine RSV	Calf, macaques	Calf [S100–S102], macaque [S103]
Tuberculosis (<i>Mycobacterium tuberculosis</i>)	Bovine tuberculosis (<i>Mycobacterium bovis</i>) zoonotic agent	Cattle	[S104]
<i>Mycoplasma pneumoniae</i>	<i>Mycoplasma bovis</i>	Calf	[S105–S107]
	<i>Mycoplasma hyopneumoniae</i>	Pig	
<i>Chlamydia</i> spp.	Respiratory infections with <i>Chlamydia</i> spp. in a variety of large animal species	Calf : <i>C. psittaci</i> , acute infection; pig: <i>C. suis</i> , acute infection; horse: chronic infection	Calf [S108–S111], pig [S112–S114], horse [S83]
<i>Pseudomonas aeruginosa</i>		Sheep (chronic infection)	[S115]
<i>Staphylococcus aureus</i> (MRSA); <i>S. aureus</i> sepsis		Sheep, pig	[S116–S118]
Lung injury induced by sepsis/septic shock		Pig	[S119, S120]

For references listed in the table please refer to the supplementary material.

which a spontaneous or induced pathological process can be investigated, and in which the phenomenon in one or more respects resembles the same phenomenon in humans or other species of animals” [25]. Different reasoning may lead to choosing one approach over another. Laboratory animals should ideally have an anatomy and physiology similar to humans, which is not always the case; much has been written about the differences between the lungs of humans, rodents, pigs and other mammalian species [26–28]. *Experimentally induced* diseases are common in the study of biology, such as bleomycin or amiodarone to mimic pulmonary fibrosis and house dust mite or ovalbumin sensitisation to mimic asthma [29, 30]. *Genetically modified* models include gain or loss of function (transgenic, knockout or knock-in), and allow to study the genetic basis of disease, its susceptibility, penetrance and resistance mechanisms. This is even more applicable if the gene variation or mutation causes the disease in both humans as well as rodents, such as in Hermansky–Pudlack syndrome interstitial pneumonia [31] or in infant respiratory distress syndrome on the basis of SFTPB or ABCA3 mutations [32]. There are some examples for *spontaneous models* in which a disorder similar to the human disease occurs naturally in animals, such as feline allergic asthma [33], pulmonary hypertension in cattle [34, 35], or pulmonary fibrosis in dogs, cats or donkeys (more examples in table 5) [36–38]. Even if models reproduce some functional features of a disease, it does not imply that they represent this disease. Similarly, models may lack specific features, but can still be valuable for understanding specific disease mechanisms.

TABLE 6 Extrapolating results from models to applications in the human disease: *in vivo* and *in vitro* variables and implications

Consideration	Variables	Implications	References
<i>In vivo</i>			
Animal species/strain	Rodent, large animal	Comparative biology of animal <i>versus</i> human lungs	[S42, S43]
	Genetic factors	Strain variation in phenotypic responses	[S44]
	Controls	Wildtype <i>versus</i> littermates	[S45]
Animal age/sex	Young <i>versus</i> old	Disease prevalence in various age groups	[S46]
	Male <i>versus</i> female	Disease prevalence in certain sex	[S46]
Housing conditions	Specific pathogen free, gnotobiotic, germ-free	Microbiome influences on phenotypic responses	[S47–S49]
	Day/night cycles	Circadian variations in phenotype	[S50]
	Variations in temperature of the housing		[S51]
	Anesthesia/euthanasia	Cellular behaviour and phenotypic responses affected by drugs	[S52–S56]
	Staff handling the animals (stress)		[S51]
	Type of exposures (intranasal/intratracheal instillation, aerosol, etc.)		[S57]
<i>In vitro</i>			
Cell type	Authentication of cell type	Skewing of conclusions if cell type tested is not correct	[S58, S59]
Culture conditions	Media	Media additives may affect cell behaviour	[S58]
	Matrices	Matrices may affect cell phenotype	[S60–S64]
	Dimensionality/mechanics	Cells behave differently in two <i>versus</i> three dimensions, and on varying stiffnesses	[S65–S68]

For references listed in the table please refer to the supplementary material.

Sex/gender representation in animal models: Lately, grant agencies (e.g. National Institutes of Health) request that preclinical research is reproduced in male and female animals to account for anticipated sex differences in humans [39]. While sex differences are important in humans, treatment effects in female and male mice offer no guarantee that the findings may be applied directly to human disease.

Structural differences between rodent and human lung: Human and rodent airways differ in anatomy and cellular composition [40]. The characteristic dichotomous branching seen in human lung is not present in the mouse. While this is relevant in areas such as aerosol drug deposition, and possibly relevant for some aspects of tissue remodelling in chronic diseases, this difference becomes less important when focus is on cellular and molecular mechanisms. Also, unlike in humans, rodent intralobular airways are lined by a simple epithelium devoid of basal cells. In mouse and rat airways, nonciliated secretory cells function as pool of renewing progenitor cells, whereas in humans, basal cells play that role [26]. Differences also exist between murine strains [41]. Innate immune responses to injury differ between mice and men, for example responses of eosinophils, granulocytes and M1/M2 macrophages [42]. Finally, the impact of the microbiome on animal health and disease, clearly being affected by housing conditions, is of great importance and needs to be taken in account.

How does the model help to draw conclusions applicable to human disease?

It is clear that “mice are not men” and extrapolating results from models to human disease should be exercised with caution. Because of the unreliability of animal models to predict human responses, an honest and accurate assessment needs to be made of the actual features of disease being modelled. Models are typically designed to mimic symptoms, disease phenotypes or key aetiological factors, such as cigarette smoke or infectious agents, rather than recapitulating the disease *per se* [43]. Certain aspects of study design established in clinical trials (e.g. randomisation, blinding) should also be used for animal studies. Failing to do so might overcome to overestimating drug efficacy in preclinical research (table 6) [44].

What are the best cell culture conditions for ex vivo research?

Numerous cell lines are available through commercial suppliers, however, the identity of some commercial cell lines has been called into question [45]. Using primary human cells is most valuable, but it is crucial to obtain proper patient consent. It should, however, be taken into account that primary cells may rapidly change their phenotypes in culture [46, 47]. Written standard operating procedures should be available for each protocol and laboratory equipment must be properly maintained. Novel techniques for cell subtyping may become a reliable future tool to do this. Rapid advances in RNA/DNA sequencing and cell isolation

already allow single-cell transcriptomic analyses, providing not only certainty about the cell type, but insights into biological processes as well as the transcriptional “states” of individual cells [48].

What approaches can translate findings from in vivo to in vitro and vice versa?

While many investigators have “taken the leap” from animal models to human trials for lung diseases, it needs to be emphasised that this is purely a “leap of faith.” Translational approaches (*i.e.* models that utilise human lung tissues *ex vivo* and *in vitro*, and animal lungs *ex vivo*) are necessary in order to understand mechanisms and pathways that underlie the observed phenotypic response [49, 50]. The task force members unanimously felt that to date, *in vitro* and *ex vivo* studies are complementary to animal models, but in most instances do not yet offer viable alternative approaches on their own. *In silico* modelling systems may have the potential to reduce animal usage in experimental research [51].

How do sampling conditions affect molecular and morphological studies?

The pre-analytic phase impacts the biological material (supplementary material contains detailed information). This includes handling and processing, the time of freezing tissues or the temperature of storing samples prior to analysis. Rigorous standard operating procedures must be followed. The effects of anaesthetic agents should be taken into account (supplementary material contains detailed information on anaesthesia and euthanasia of rodents); for instance, depression of respiration can lead to hypercapnia, hypoxia and acidosis, all of which may impact on cytokine production and regulation, among others (supplementary material).

Can large animals help the modelling of respiratory diseases?

Large animal models are thought to offer high biological relevance due to size and anatomical similarities to humans (table 5). However, the validity of this assumption has not yet been systematically analysed. Sometimes, the study of large animals may not only benefit human, but also animal, health. Although in agreement with the 3R concept and the requirements of animal welfare, models employing domestic animals are usually less well accepted. Further, large animal models are costlier, with fewer available reagents and gene manipulations, than rodents (for more information on large animal models please refer to the supplementary material).

Task force statements

- Mechanistic pathways observed *in vitro* might not be replicable *in vivo* but can provide important mechanistic/biological responses.
- The use of multiple models is required in many situations to facilitate reliable conclusions.
- Statistical significance does not prove biological significance.

Recommendations for experimental research in respiratory diseases

- Clearly and *a priori* define the end-points of each study.
- Explicitly define if the model used is exploratory or as part of a drug/device trial where power calculations are needed to obtain reliable statistical results. Experimental conditions (such as temperature/anaesthesia) should be well documented to allow for comparison between data and reproducibility of results.
- Researchers should be aware of novel techniques to characterise the cells they study *in vitro*.

Gene editing

Genetic manipulation, especially editing of endogenous or introduction of exogenous genes, are powerful tools, not only for the study of gene function *in vivo*, but also for generating models that resemble pathological conditions (figure 3). However, epigenetic and environmental factors can both affect the phenotype of genetically altered animals, which might explain why outcomes using the “same” mouse may vary between laboratories. Lack of experimental reproducibility due to these variable factors must be given serious consideration in research.

Does genetic background affect phenotypic presentation?

Gene editing of the same gene in mice by different groups often have dissimilar phenotypes. The background strain is an important factor, the conventional transforming growth factor- β 1 knockout mouse being one example (table 7). Knockout groups must have the same genetic background, which can be achieved by backcrossing. For repetitive studies, it is best to keep the mice to the same strain background. In contrast, for initial phenotypic screening of a new genetically edited mouse line, different backgrounds may be useful to understand its entire genetic functions.




FIGURE 3 Gene editing. Summary of approaches used in mouse gene manipulation and resulting genetic changes. NHEJ: nonhomologous end joining; HDR: homology-directed repair.

How does the same transgene cause variable phenotypes?

Transgenic mice are commonly generated by injection of a DNA construct directly into the pronucleus of a fertilised single cell embryo, in which the transgenic DNA is randomly integrated into the mouse genome. Promiscuous expression patterns of the transgene have been reported, possibly due to modification of the transgene promoter by the surrounding genomic components, disruption of a gene at the integration site, different copy number of the inserted transgene, or even epigenetic complication in germ cells of the transgenic parents. For example, 25 different expression patterns were reported in Thy1-XFP transgenic mice derived from 25 different founders [52]. Therefore, full characterisation of each transgenic mouse line is mandatory. When using gene knock-in or an integrase-based approach, site-specific single copy transgene can be introduced to the mouse genome [53].

How do variable phenotypes occur in the same gene conditional knockout?

Cre/loxP is the most frequently used system for creating conditional gene knockouts [54] with cell-specific and inducible deletion. Many of the Cre driver lines used in research (table 8) are transgenic mice with the caveats discussed above. Cell type specificity of a floxed-gene deletion that is induced by the same Cre driver line may vary between ages. For example, lung mesenchymal cells are differentially targeted by the Tbx4-lung enhancer depending on the induction ages [55]. In addition, inducing agents used in gene manipulating systems (e.g. tetracycline for the Tet-on or Tet-off transcription system and tamoxifen for CreER activation) may have off-target effects. It has, for instance, been reported that doxycycline affects airway epithelial cell differentiation and alveolar development in certain backgrounds [56–59]. Doxycycline

TABLE 7 Genetic models are affected by background; phenotypic presentation of transforming growth factor- β 1 knockout in mice with different strains

Strains	Phenotypes
129/Sv x CF-1	50% mutants died embryonically, the rest survived postnatally, with massive inflammation primarily in heart and lung by 3–4 weeks of age [S121]
C57BL/6	All mutants died during preimplantation [S122]
129/Sv x C57BL/6 x NIH/Olac	50% mutants died of preimplantation, the rest died of a yolk sac developmental defect [S123]

For references listed in the table please refer to the supplementary material.

TABLE 8 Some cell type-specific Cre mouse lines used in lung research

Mouse line [Ref.]	Targeted cells in lung tissue	Lung specificity
Shh-Cre [#] [S124]	Ventral foregut endoderm-derived lung epithelial cells	No
Nkx2-1-Cre [S125]	Lung endoderm-derived epithelial cells	No
Sftpc-CreER ^{T2#} [S126]	Fetal airway epithelial cells and postnatal type II alveolar epithelial cells	Yes
SFTPC-Cre [S127]	Fetal lung epithelial cells	Yes
SFTPC-rtTA/TetO-Cre [S128]	Fetal airway epithelial cells and postnatal type II alveolar epithelial cells	Yes
Aqp5-Cre [#]	Type I alveolar epithelial cells	No
Hopx-CreER ^{T2#} [S129, S130]	Type I alveolar epithelial cells	No
Scgb1a1-Cre [S131]	Club cells	Yes
Scgb1a1-rtTA/TetO-Cre [S132]	Club cells and some type II alveolar epithelial cells	Yes
Scgb1a1-CreER [#] [S133]	Club cells and some type II alveolar epithelial cells	Yes
FOXJ1-Cre [S134]	Ciliated epithelial cells	No
FOXJ1-CreER ^{T2} [S135]	Ciliated epithelial cells	No
KRT5-CreER ^{T2} [S136]	Basal cells	No
Dermo1-Cre [#] [S137, S138]	Mesoderm-derived lung mesenchymal cells	No
Tagln-Cre [S139]	Smooth muscle cells (pulmonary vasculature)	No
Acta2-Cre [S140]	Smooth muscle cells	No
Myh11-CreER ^{T2#} [S141]	Smooth muscle cells	No
Tbx4-rtTA/TetO-Cre [S142]	Lung mesenchymal cells	Yes
Tbx4-CreERT [S143]	Lung mesenchymal cells	Yes
Pdgfrb-Cre [S144, S145]	Perivascular progenitor and smooth muscle cells, and pericytes	No
Cspg4-Cre [S146]	Vascular smooth muscle cells and pericytes	No
Wt1-Cre [S147]	Mesothelial cells	No
Tek-Cre [S148]	Endothelial cells	No
Lyve1-Cre [#] [S149]	Lymphatic endothelial cells	No
Prox1-CreER ^{T2} [S150]	Lymphatic endothelial cells	No
Wnt1-Cre [S151]	Lung intrinsic neurons	No
Ascl1-CreER ^{T2#} [S152, S153]	Pulmonary neuronal endocrinal cells and some airway and alveolar epithelial cells	No

[#]: knock-in mice; [¶]: transgene in Y chromosome. For references listed in the table please refer to the supplementary material.

also inhibits matrix metalloproteinases [60], reduces airway mucin production, and attenuates neutrophil influx into the lungs upon endotoxin challenge [61–63]. In addition, doxycycline is an antibiotic that may affect the bacterial flora and microbiome, which play important roles in experimental mouse phenotypes [64, 65]. In the case of tamoxifen, early embryonic administration can cause nonspecific phenotypes, while late administration induces early delivery of fetuses [66]. In adults, high dose tamoxifen can cause transient hypertension and cardiomyopathy [67, 68].

The mammalian genome also contains cryptic “pseudo-loxP” sites, which may be recombined by Cre recombinase, resulting in loxP-independent genomic alteration with nonspecific effects [69, 70]. In contrast, deletion of floxed-gene may occur in offspring including those without inherited Cre genotype (or germline leakage) [71–74], which may be due to transmission of Cre RNA or protein in the oocyte or sperm from transgenic parents.

What are the potential issues in the Crispr/Cas9 approach?

A novel approach using RNA-guided clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein 9 nuclease (Cas9) has been successful in genome editing [75]. Guided RNA (gRNA) recognises specific sequences in the genome and activates Cas9 to induce a DNA double strand break. Changes in genomic DNA can be achieved by either nonhomologous end joining or homology-directed repair. Due to potential nonspecific binding of gRNA to undesired genomic DNA, off-target effects are a major issue. Although Cas9 has been modified in order to circumvent this problem [76, 77], additional experiments may be needed to validate the data, such as rescuing the phenotype by reintroducing that particular wildtype gene or generating the mutation in the same gene by targeting different sites.

Task force statement

- Gene editing in mice is extremely valuable for the study of gene function and generating disease-like models.

- Genetic, epigenetic, age and sex, and other factors (including incomplete gene knockout with “leaking”) may affect the phenotypic presentation.

Recommendations for experimental research in respiratory diseases

- Use appropriate controls and complementary approaches to validate the data.

Specific aspects about modelling individual pulmonary diseases

The considerations covered so far are applicable to all areas of experimental research. Individual diseases have specific features that need to be considered when developing experimental models. The task force addressed key questions focused on common respiratory disorders (asthma, COPD, pulmonary fibrosis, infections, ALI/ARDS and pulmonary hypertension). The major unmet needs for the disease area are discussed and specific subgroups are explored. We also addressed how suitable the models are for testing and validating the efficacy of new drugs.

Asthma

How do we define asthma for experimental research?

“Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation, and defined by the history of respiratory symptoms (wheeze, shortness of breath, chest tightness and cough) that vary over time and in intensity, together with variable expiratory airflow limitation” [78]. Separate, but sometimes overlapping, phenotypes exist, and both environment (*e.g.* microbial exposure during infancy known as the “hygiene hypothesis” or air quality) and genetic predisposition are important in asthma development [79]. Asthma is classified based on age at onset, type of inflammation, presence of allergy, sensitivity to non-steroidal anti-inflammatory drugs and obesity [80]. Inhaled corticosteroids (ICS) combined with long-acting β 2-adrenergic agonists (LABA) are the cornerstone in asthma treatment, but are not beneficial to all asthma endotypes (defined by distinct functional or pathophysiological mechanisms [81]). Classical murine models mimicking the common aspects of the disease, *i.e.* airway inflammation and remodelling, IgE production, airway hyperresponsiveness (AHR) [82, 83], are not modelling the complex reality of asthma.

What are the major unmet needs for modelling and studying asthma?

The acute allergen-driven airway inflammation models have provided important insights into early-onset eosinophilic allergic asthma and type 2-mediated immune responses [82]. This task force puts forward three unmet needs to be further explored experimentally [80, 84]. 1) Chronic asthma and remodelling: models showing chronic inflammation, airway narrowing and AHR, with bronchi exhibiting subepithelial fibrosis, smooth muscle hypertrophy and hyperplasia, altered airway epithelium, goblet cell proliferation and mucus hyperproduction. 2) Severe asthma and exacerbations: models with sustained inflammation, remodelling and AHR despite ICS-treatment, and models with a progressive aggravation of disease (*e.g.* upon viral challenge). 3) Non-type 2 asthma: models with neutrophilic (often Th1/Th17-driven), mixed eosinophilic/neutrophilic or paucigranulocytic bronchial inflammation; models with low sensitivity to corticosteroids and low resolution of inflammation. Strengths and limitations of these new asthma models, including age, sex, strain, hygiene in animal facility, exposures and outcome parameters (invasive pulmonary function measurements, inflammation and remodelling, severity, sensitivity to corticosteroids) need to be acknowledged [83, 85–90].

How can we model specific clinically relevant phenotypes/endotypes of asthma?

Real life conditions should be included in the models, in particular chronic exposure to allergen [83, 91, 92], cigarette smoke [93, 94], air pollution [95–97], viruses (or viral-RNA) [98, 99] or bacteria/endotoxins [100–103]. In addition, the importance of obesity, age (neonatal and aged mice) and the microbiome in asthma onset and progression should be taken into account (table 9) [104, 105]. The advantages and disadvantages of specific animal species in experimental models of asthma should be considered [106]; *e.g.* for investigating early and late asthmatic responses, neuronal aspects and cough, including activity of β 2-bronchodilators and pharmacological studies, research in the guinea pig can provide important insights [107–109]. *In vitro/ex vivo* analyses and cell culturing systems [23, 110, 111] are complementary and crucial in view of the 3Rs.

How suitable are asthma models for testing and validating the efficacy of new drugs?

The new insights in asthma phenotypes and endotypes obtained have yielded to selection of the right patients for the right drug with a need of careful patient stratification in study design. Indeed, whereas for example anti-IL-5 (developed from acute allergen-driven type 2 models) initially “failed” in the first preclinical trials [112], careful patient selection has led to successful application in patients with severe

TABLE 9 Asthma: a review from the literature of the different *in vivo* murine models used to study specific aspects of asthma pathogenesis

Area of research	Main focus	Main experimental tools	References
Th2 asthma			
Sensitisation	Adjuvants (alum, CFA, none), mechanism	Knockout mice and cell depletion to evaluate role of innate immune cells	[S154, S155]
	LPS, particulates and tobacco smoke	OVA or HDM models, Ig measurements and airway inflammation; knockout mice	[S156–S158]
	Atopic march (skin or gastrointestinal barrier)	Atopic dermatitis or food allergy models followed by airway challenge, effects of antibiotic treatment, germ-free mice, mice with impaired recognition of microbial components	[S159–S163]
Epithelium	Active role of barrier in defence and inflammation	OVA, HDM or <i>Alternaria</i> models, depletion of epithelial cells (naphthalene), specific knockout mice or inhibitors, inflammatory response, AHR, airway permeability, remodelling	[S164–S169]
Inflammation	Eosinophils, neutrophils	OVA or HDM models, conditional eosinophil deficient or transgenic mice, cell depleting antibodies, cell recruitment	[S170–S176]
	Mast cells	OVA or HDM models, cell migration, knockout mice (mast cell deficient or deficient in key mediators)	[S163, S177–S184]
	Dendritic cells, macrophages, basophils	OVA or HDM models, allergen-pulsed antigen-presenting cells, cell depletion (e.g. clodronate, diphtheria-toxin), neutralising antibodies, chimeric experiments, adoptive transfer experiments, cell migration, cell proliferation	[S163, S185–S201]
	Th2 cells, Th17, Th22, Th9, B-cells	OVA, HDM or <i>Aspergillus fumigatus</i> models, IL-4 reporter mice, transgenic mice, allergen-pulsed antigen-presenting cells, specific cell knockout mice, neutralising antibodies	[S202–S209]
	Innate lymphoid cells	Papain, OVA, HDM, glycolipid antigen models or models with a combination of allergens, effects of route of sensitisation, cell knockout mice, adoptive transfer experiments, neutralising antibodies	[S210–S215]
AHR	Platelets	Papain model, adoptive transfer experiments	[S216]
	AHR to allergen or to bronchoconstrictor, mechanisms	OVA or HDM models or IL-13 inoculation, transgenic or knockout mice to evaluate role of smooth muscle in AHR, adoptive transfer	[S208, S217–S223]
Remodelling	Mucus hypersecretion/goblet cell hyperplasia; epithelial disruption/injury; smooth muscle proliferation; collagen deposition; angiogenesis	OVA or HDM models, models with allergen-pulsed antigen-presenting cells, xenograft model, mechanisms, neutralising antibodies, knockout mice, immunohistochemistry	[S205, S219, S224–S233]
Hygiene hypothesis, mechanisms	Bacterial or parasite triggers, farm dust; regulatory dendritic cells, T-cells and macrophages	OVA, HDM or grass pollen models, knockout mice, cell trafficking, adoptive transfer experiments, neutralising antibodies	[S157, S159, S234–S245]
Host-related factors	Age, metabolism, microbiome (lung-gut interaction), sex, genetic susceptibility, prenatal exposure	OVA, HDM or <i>Aspergillus</i> models, hyperalimentation model, inflammation or inflammatory cytokine and AHR, different mouse strains, cell depleting antibodies, knockout mice, germ-free mice <i>versus</i> specific pathogen-free mice	[S159, S232, S246–S260]
Treatment opportunities			[S223, S233, S261–S278]

Continued

TABLE 9 Continued

Area of research	Main focus	Main experimental tools	References
Asthma-modelling	Targets, mechanisms, cytokine, chemokine receptors, proteases, transcription factors Acute and chronic models	OVA, HDM, cockroach models, neutralising antibodies or small compounds, knockout mice, siRNA, miRNA, peptide vaccination, bone marrow chimeras inflammation and AHR OVA, HDM, fungi (e.g. pneumocystis, <i>Aspergillus</i> , <i>Alternaria</i>), cat allergen, cockroach, combinations of dust mite, ragweed and <i>Aspergillus</i>	[S169, S176, S256, S262, S270, S279–S283]
Disease persistence versus resolution, tolerance Inflammation, chronicity, persistence of AHR and/or remodelling	Mechanisms of resolution, regulatory T-cells, role for dendritic cells	HDM and OVA models, antigen-pulsed macrophages or dendritic cells, adoptive transfer of enriched cell populations, cell depletion by monoclonal antibodies, neutralising antibodies, inflammation and AHR	[S194, S209, S213, S231, S281, S284–S287]
Asthma exacerbations Viral infection, poly (I:C), epithelial cytokines Fungi (<i>Aspergillus</i> , <i>Alternaria</i> , mycotoxins) Bacterial infection, LPS Air pollutant (ozone, particulates, tobacco smoke, NO ₂)	Innate responses, inflammation, AHR Inflammation, AHR, remodelling Innate responses, inflammation, AHR Mechanisms of pollutant aggravated airway disease (inflammation, AHR, remodelling)	OVA or HDM models, knockout mice, TLR ligands, neutralising antibodies, antagomiRs OVA and mycotoxins OVA or HDM models, knockout mice, TLR ligands OVA or HDM models, knockout mice, blocking antibodies	[S249, S288–S299] [S256, S300, S301] [S158, S290, S291, S302] [S156, S303–S312]
Severe asthma models and mixed Th1/Th2/Th17 or non-Th2 asthma models Uncontrolled asthma, insensitivity to glucocorticosteroids	Mechanistic insights, treatment opportunities, mixed inflammation	HDM or OVA models, combined with bacterial, viral triggers or pollutants (see above); blocking antibodies, (conditional) knockout mice, depletion of inflammatory cells, Th2/Th17 cell transfer, new therapeutic options Chlorine- or isocyanate-induced inflammation and AHR, neutrophilic inflammation by intranasal instillation of cytokines	[S170, S218, S221, S288, S290, S293, S297, S299, S305, S306, S308, S313–S321]
Cough (guinea pig) Cough related or unrelated to asthma, airway reflexes	Mechanistic insights, neurogenic responses, early and late asthmatic, responses treatment opportunities	OVA models, inhalation of cough-inducing agents, AHR and cough, therapeutic interventions	[S322–S326]

Th: T-helper; LPS: lipopolysaccharide; OVA: ovalbumin; HDM: house dust mite; Ig: immunoglobulin; AHR: airway hyperresponsiveness; IL: interleukin; TLR: Toll-like receptor. For references listed in the table please refer to the supplementary material.

eosinophilic asthma [113] with the approved anti-IL-5 mepolizumab, reslizumab and anti-IL-5R α benralizumab. In addition, these clinical insights have highlighted the necessity for new drug development for specific patient groups. The novel animal models aim at unravelling the complexity of asthma pathophysiology, and facilitating pharmacological research focussing on difficult-to-treat asthma phenotypes.

Task force statements

- One asthma model cannot mimic the whole disease, but the diversity in models will provide opportunities to mimic the various aspects and the heterogeneity of asthma.
- Multiple preclinical asthma models are applied for targeting specific patient groups/clinical parameters.

Recommendations for experimental research in respiratory diseases

- Select specific models for the parameters of interest to increase the clinical relevance and applicability of asthma models.

COPD

How do we define COPD for experimental research?

According to the Global Initiative for Chronic Obstructive Lung Disease, “COPD is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced inflammatory response in the airways and lung to noxious particles and/or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients” [114]. Recent reports have provided longitudinal insight into the evolution of airway obstruction. These studies showed that the rate of decline in forced expiratory volume in 1 s is highly variable among COPD patients, with only a fraction showing an accelerated decline [115]. Moreover, approximately half of the COPD patients have decreased lung functions in early adulthood, with a normal decline afterwards [116], suggesting an early origin of COPD [117]. Current and former smokers with preserved lung function may still present respiratory symptoms, exacerbations and activity limitation [118]. These different phenotypes need to be taken into consideration when modelling COPD.

What are the major unmet needs for modelling and studying COPD?

Exposure of animals to cigarette smoke is one of the most relevant models for the study of smoking-associated inflammation and lung pathologies [15, 119–129]. Less well understood is how these inflammatory processes contribute to accelerated decline in lung function, how they persist following smoking cessation, and why they cause predominant airway *versus* parenchymal disease in subgroups of individuals. Emphasis also needs to be placed on how to repair/restore damaged parenchymal tissues. Given the early origin of COPD [117], there is a need to study the contribution of lung development, including bronchopulmonary dysplasia in the genesis of the disease. The limitation of most *in vivo* smoke models in mice do cause emphysema but no/little airway disease, and while major attention has been paid to tobacco smoking, COPD can also be caused by exposure to other noxious particles and gases, including biomass fuels and air pollutants [130]. A key question that emerges is whether exposure to any noxious particles and gases results in similar or differing pathogenic mechanisms and disease phenotypes. Modelling acute exacerbations of COPD in animals has proven challenging due to the clinical and pathological complexity of the underlying disease and the fact that exacerbations have a variety of causes and severities (supplementary material) [131]. There is a further need for models of COPD-associated comorbidities.

How can we model specific clinically relevant subgroups of COPD?

The pathogenesis of COPD is the result of a complex series of events perpetrated over decades [114–116]; hence, experimental models, such as exposure to cigarette smoke, and various environmental and indoor air pollutants, as well as the intratracheal administration of proteolytic enzymes, provide the opportunity to examine specific facets of the disease and study them in isolation from confounding factors. The strengths of these models are a mirror of their weaknesses. The reductionist emulation of a subset of pathogenic components fails to mimic the complexity of the disease. This is an important consideration when translating observations from experimental models to human disease. There is also a need to stratify COPD studies by sex [132]. Experimental studies have access to a broad range of reagents, tissues and intervention strategies that are not available or feasible in clinical research. This has helped to investigate mechanisms of inflammatory processes and emphysema formation [15, 119–129], and implicated protease/anti-protease balance, oxidants/anti-oxidants, apoptosis/proliferation, matrix destruction/deposition, pro-/anti-inflammatory mediators, lung development (early origin), accelerated ageing, and autoimmune mechanisms in the pathogenesis of COPD (table 10). Similarly, animal models of viral or bacterial infection, and concurrent cigarette smoke exposure have contributed to our understanding of

TABLE 10 Chronic obstructive pulmonary disease (COPD): a review from the literature of the different multi-model combination systems used to study a specific aspect of COPD pathogenesis

Area of research	Main focus	Main experimental tools	References
Genetic factors	Alpha-1-antitrypsin	Cigarette smoke exposure of different mouse strains, gene deletion and transgenic overexpression	[S327–S330]
	GWAS loci associated with COPD	Cigarette smoke exposure, gene deficient mice, <i>in vitro</i> experimentation	[S331–S334]
Lung development	Lung growth	Gene deficient animal models	[S331, S335–S343]
	Maternal smoking during pregnancy	Cigarette smoke exposure	[S344–S347]
Environmental factors	Ageing	Cigarette smoke exposure	[S348, S349]
	Tobacco smoke exposure	Cigarette smoke exposure	[S350–S358]
		<i>In vitro</i> systems	[S350, S359]
	Biomass fuel	Wood burning smoke exposure	[S360]
		Exposure to wood or cow dung particulate matter	[S361]
	Outdoor pollution	Exposure to air pollutants	[S351, S362–S364]
Microbial agents	LPS administration	[S365–S370]	
Airway remodelling	Airway and vascular remodelling	Cigarette smoke exposure	[S371, S372]
	Airspace enlargement	Transgenic mouse strains	[S371, S373, S374]
Alveolar destruction/ emphysema		Instillation of elastases	[S353, S374, S375]
		Cigarette smoke and bacterial agents	[S376–S381]
Exacerbations	Bacteria-predominant	Cigarette smoke and viral agents	[S295, S382–S389]
	Viral-predominant		
Comorbidities	Cachexia/skeletal muscle wasting, cardiovascular		[S353, S390–S395]

GWAS: genome-wide association study; LPS: lipopolysaccharide. For references listed in the table please refer to the supplementary material.

mechanisms of COPD exacerbations [119, 123, 133–135]. Animal models have also been used to study COPD-associated comorbidities [121, 127, 136]. Thus, although experimental models have provided insight into putative pathogenic mechanisms associated with COPD, successful translation of these observations from bench to bedside will require an improved understanding of the relevance of experimental models relative to specific COPD phenotypes.

How suitable are COPD animal models for testing and validating the efficacy of new drugs?

COPD encompasses a spectrum of obstructive lung diseases of different origins and phenotypes. No single experimental model reflects this complexity. Choosing the appropriate animal model requires an in-depth understanding of the research question, the strengths and limitations of the corresponding models, and selection of clinically relevant end-points [121]. Drugs developed using this approach will likely not be suitable for all COPD patients, but be effective in specific patient subpopulations. To date, experimental models have reflected the usefulness and limitations of a number of anti-inflammatory agents that are used clinically, including steroids and phospho-diesterase-4 inhibitors [121].

Detailed information regarding COPD is available in the supplementary material.

Task force statements

- No single experimental model reflects the overall complexity of COPD.
- Current experimental models can be used to study specific clinical phenotypes.
- Modelling COPD requires a better understanding of the different clinical phenotypes and selection of clinically relevant end-points.
- There is a lack of experimental models to investigate mechanisms of COPD unrelated to smoking effects.

Recommendations for experimental research in respiratory diseases

- There is no “best model” of COPD. Experimental models should be selected to address specific research question and interpreted accordingly.

Pulmonary fibrosis

How do we define pulmonary fibrosis for experimental research?

Pulmonary fibrosis refers to a diverse group of lung and pleural disorders characterised by the accumulation of extracellular matrix. Pathological fibrosis is distinct from normal wound healing and

TABLE 11 Pulmonary fibrosis: a review from the literature of the different multi-model combination systems used to study a specific aspect of fibrosis pathogenesis

Model system	Characteristics	References
Mouse	Strain dependency to developing fibrosis: resistance (CBA/j, Balb/c) and susceptibility (C57Bl/6)	[S396]
	Various exogenous insults (bleomycin, TGF- β , radiation, silica, etc.) and routes of administration (intratracheal, intraperitoneal, external beam, subcutaneous)	[S396]
	Transgenic capabilities to assess individual molecules or pathways	[S396]
Sheep	Bronchoscopic instillation of bleomycin allows for focal injury, repeated assays, and using an animal as its own control; histology shows patchy fibrosis but no fibroblastic foci or honeycomb cysts	[S32, S397]
West Highland white terriers (and other terrier breeds), domesticated felines, adult horses	Naturally occurring cases of parenchymal pulmonary fibrosis have been documented in various animal species and breeds; although little is known about pathogenesis in these models, they may be useful to study various aspects of fibrogenesis	[S398]
Aged donkeys	Naturally occurring cases of pleuropulmonary fibroelastosis have been observed in aged donkeys; little is known about pathogenesis in this model	[S399]
Acellular human lung slices	Maintains normal spatial resolution and matrix composition	[S60, S400–S403]
Precision-cut lung slices	Study of living lung tissue allows for measuring responses to potential therapeutic or pathogenic agents	[S404–S406]
In silico modelling	Computer-based analysis of stress-strain and physical force relationships in lung parenchyma, can be used to predict how lung compliance may worsen or improve over time in fibrotic diseases	[S407]

TGF: transforming growth factor. For references listed in the table please refer to the supplementary material.

scarring because of the progressive nature and typical diffuse organ involvement leading to dysfunction. Animal models typically only resemble a few aspects of the human disease. Multiple variables (genotype, age, sex, smoking, etc.) in the human condition prohibit any single model from being the “correct model.” Absolute transparency in protocols and experimental design is therefore paramount. Despite their popularity, mice may not be the ideal animal to study fibrogenesis. It is incorrect to say that “the murine bleomycin model is a model of IPF” since the cardinal features of IPF (namely progressive fibrosis, honeycombing and fibroblastic foci) do not develop in this model [137]. The model choice should be dictated by the particular aspect of fibrosis under scrutiny, and this should be explicitly stated in research proposals and publications, with full acknowledgement of the strengths and weaknesses of the models selected. Suggested readouts for studies have been recently described [138].

What are the major unmet needs for modelling and studying pulmonary fibrosis?

Unmet needs include a better understanding of the mechanisms that govern human lung fibrosis and improved models that gradually develop progressive fibrosis. Mice, rats and hamsters have been used for decades to model pulmonary fibrosis due to the availability of reagents, low costs, the relatively short time span needed to study fibrogenesis, and the ability to manipulate the genome. However, significant differences between human and mouse lungs question the appropriateness of murine lungs as valid surrogates of human lungs [26, 27, 139]. Large animal models, using ferret, pig and sheep have been described with phenotypes that appear more congruent with human pulmonary fibrosis [140–144]. Further, naturally occurring pulmonary fibrosis models exist [37, 38, 145–152], which may offer insights into pathogenesis and systems to test therapeutic agents.

How can we model specific subgroups of pulmonary fibrosis (pleural fibrosis, hypersensitivity pneumonitis, connective tissue disease-associated pulmonary fibrosis, etc.)?

Understanding the aetiologies of various fibrotic diseases is critical. Ideally, disease modelling will result in actionable information on how to interfere clinically. It may be possible to recapitulate salient disease features when the aetiology is known (e.g. radiation pneumonitis). Still, even with the aetiology known (such as hypersensitivity pneumonitis), experimental lung disease may or may not occur after exposure. A detailed understanding of the immunological mechanisms underlying the disease (such as genetic predisposition, environmental factors or exposure duration) is necessary to create an appropriate model (table 11). Substantial resources are needed to improve “standard” models of pulmonary fibrosis and advance scientific knowledge.

How suitable are these models for testing and validating the efficacy of new drugs?

For preclinical testing purposes, the task force advocates for the development of experimental systems that can be used when triggering mechanism and the secondary pathomechanistic steps are known. When both are unknown and only hypothesised, it is preferable to use models to address specific aspects of pulmonary fibrosis, including prevention of fibrosis and treatment of established fibrosis to gauge reversibility. Multiple models (*in vivo*, *ex vivo*, and high-throughput systems such as PCLS) should be considered. For instance, pirfenidone, the first approved drug for IPF [153], has been extensively tested in various preclinical models (bleomycin in hamster, mouse and rats) [154]. Similarly, nintedanib [155] had also proved its efficacy in several models (bleomycin in rats and mice, silica in mice) [154].

Task force statement

- Pulmonary fibrosis generally develops in phases; defining the phasic nature of individual models is necessary when planning experiments to ensure that the area of study reflects the stage of fibrosis being assessed.
- A single readout of a single model is insufficient to draw conclusions about the efficacy of an intervention in pulmonary fibrosis models.
- A particularly valuable aspect of animal models of pulmonary fibrosis is to use them to develop pharmacodynamic biomarkers. Namely markers that demonstrate target engagement that can be readily translated in clinical trials.

Recommendations for experimental research in respiratory diseases

- There is no “best” model of pulmonary fibrosis. Models should be chosen to answer a specific research question, not to investigate a specific disease state, and should be interpreted with the limitations of such models in mind.
- Multiple readouts in multiple models such as imaging, lung function, and pathophysiological data should be available before drawing strong conclusions.

Pulmonary infections***How do we define pulmonary infections for experimental research?***

Pneumonia is associated with high morbidity and mortality. Novel antibiotics and therapeutic strategies beyond antibiotics are needed and disease models are instrumental in order to achieve this. Clinically, pneumonia is induced by viable pathogens that spread and replicate in the lungs, and frequently involves systemic inflammation with extrapulmonary organ pathology (table 12). Pneumonia has to be distinguished from colonisation. The causal pathogens vary, with *Streptococcus pneumoniae* being most prevalent in community-acquired pneumonia (CAP) [156–159], and *Pseudomonas aeruginosa* being among the most common pathogens in hospital-acquired pneumonia (HAP) [160]. The pathogens and their serotypes determine the lung phenotype. More than 90 *Streptococcus pneumoniae* serotypes have been identified [161], with major differences in virulence profiles. Therefore, the chosen serotype defines the developing disease entity. Several techniques are available for the delivery of pathogens into the lungs of animals, such as intranasal instillation [162, 163], intratracheal aspiration *via* oropharyngeal tube [164–172], and surgical exposure of the trachea followed by direct bacteria injection into the airway lumen [173, 174]. Factors to be considered include the stress associated with the procedure, the dose of bacteria administered, the possibility of inducing infections other than pneumonia, the impact of the injection volume and differences in the immune system of the host.

What are the major unmet needs for modelling and studying lung infections/pneumonia?

The lungs are composed of numerous different cell types; the respiratory epithelial layer alone may contain nearly 50 different cell types [175]. For modelling of pathogen–host interaction, cells in culture need to represent their *in situ* counterparts in appearance, gene expression, function and signalling pathways. Moreover, interactions between recruited cells and the pathogen, and local cells, represent a major challenge [176]. Thus, at present, caution needs to be exercised when extrapolating *in vitro* results from simple epithelial cell culture to the *in vivo* situation. Intrinsic host susceptibility to infection is influenced by sex, age and comorbidities [177, 178], among others, and also by species and mouse strains [179–185]. Such variables need to be controlled in experimental pneumonia studies. Greater emphasis should be placed on clinically relevant cofactors. Finally, the microbiota is influenced by environmental factors (*e.g.* husbandry practices, specific pathogen free units, *etc.*) and has significant impact on the outcome of animal experiments [186]. Thus, all animals required for one experiment must be housed in exactly the same environment, in parallel, to reduce the influence of the microbiota on the course of pneumonia.

TABLE 12 Characteristics of specific mouse models of pulmonary bacterial and viral infection (fungal infections were omitted due to space constraints)

Pathogen	Characteristics	Reference
<i>Streptococcus pneumoniae</i>	Various serotypes used experimentally, primarily serotypes 1 and 3 Many other serotypes avirulent in immunocompetent mice CBA/J mice susceptible to several clinical isolates of <i>S. pneumoniae</i> without immunosuppression Pneumococcal disease in mice with <i>S. pneumoniae</i> strain-dependent pathogenesis: <i>S. pneumoniae</i> serotype 2 (D39): bacteraemia/high-grade sepsis <i>S. pneumoniae</i> serotype 3 (A66.1): pneumonia progressing to bacteraemia and sepsis <i>S. pneumoniae</i> serotype 4 (TIGR4): low-grade pneumonia and bacteraemia, progressing to meningitis Anaesthetic-dependent severity of disease (pneumococcal strain-independent): more severe forms of pneumococcal disease in mice anaesthetised with ketamine/xylazine compared to isoflurane Mouse strain dependency to intranasal pneumococci serotype 2 (D39): resistance (e.g. BALB/c mice) or susceptibility (e.g. CBA/Ca mice) is suggested to be associated with recruitment and/or function of neutrophils	[S408–S410] [S411] [S411] [S412]
<i>Klebsiella pneumoniae</i> serotype 2 (ATCC 43816 lab strain)	Bacteraemia	[S413–S415]
<i>K. pneumoniae</i> clinical isolate (e.g. TOP52)	Mortality likely due to sepsis rather than to respiratory failure Largely survivable and contained to the respiratory tract (only 11% bacteraemia 24h p.i.; proportion similar to that observed in human pneumonia) Histologic features of TOP52-infected lungs 24h p.i. parallel those observed in human disease	[S416, S417]
<i>Legionella pneumophila</i> serogroup 1 (strain JR32)	Restriction of bacterial replication during acute infection phase in mice due to flagellin-mediated activation of the NAIP5/NLRC4 inflammasome	[S418]
Flagellin-mutants of <i>Legionella pneumophila</i> JR32	Efficient pulmonary infection with <i>Legionella</i> replication in the lungs	[S419–S422]
<i>Pseudomonas aeruginosa</i>	No mortality in infected mice even at high infection doses Pneumonia with histopathology similar to human infection Infection dose-dependent pneumonia severity/lethality following intratracheal inoculation of <i>P. aeruginosa</i> PA01 Chronic infection model by intratracheal inoculation of <i>P. aeruginosa</i> enmeshed in agar or seaweek beads Lung pathology similar to that seen in cystic fibrosis patients with advanced chronic disease Mouse strain-dependent differences in the course and outcome of chronic pulmonary infection (e.g. resistant BALB/c mice versus susceptible C57BL/6 mice) Sex differences in susceptibility to <i>P. aeruginosa</i> (strain 508) lung infection in C57BL/6 mice	[S423] [S424] [S425, S426] [S427–S430] [S431]
<i>Chlamydia pneumoniae</i>	Interstitial pneumonitis following intranasal inoculation of <i>C. pneumoniae</i> (strain AR-39) in Swiss Webster mice Mouse strain-dependent course of lung infection Nonfatal, prolonged course of lung infection in Swiss Webster mice after intranasal inoculation 50% mortality in C57BL/6 mice Systemic dissemination following intranasal inoculation of <i>C. pneumoniae</i> (strain AR-39) Lesions of atherosclerosis as complication Cell-associated bacteraemia following intranasal or intraperitoneal inoculation of <i>C. pneumoniae</i> (strain AR-39) Severe pneumonia in BALB/c mice followed by recovery after intranasal application of <i>C. pneumoniae</i> CWL029 (ATCC VR-1310) Culture-dependent chlamydial (CWL029) virulence alteration Interstrain differences in virulence of laboratory strains of <i>C. pneumoniae</i> High-virulent strains (Kajaani-K6, CWL-029) Low-virulent isolate (TWAR-183)	[S432, S433] [S433–S435] [S434] [S436] [S437] [S438]
Influenza virus	Manifestation as a primary viral pneumonia Clinical signs of influenza virus infection in mice differ from those of typical human influenza (e.g. hypothermia versus febrile response) Mouse-adapted viruses are needed to induce clinically apparent disease in mice Mouse strain-dependent differences in host response to infection with influenza virus	[S439–S441] [S442–S444]

For references listed in the table please refer to the supplementary material.

How can we model relevant phenotypes (e.g. local versus systemic infection) in pneumonia?

As examples, the disease entity in mice following transnasal pneumococcal inoculation is defined by the chosen serotype, which should be selected with respect to the clinically relevant phenotypes, such as pneumonia with and without bacteraemia, sepsis or ARDS [187–189]. The clinical scenario of mechanical ventilation of patients with acute respiratory failure (due to pneumonia) can also be studied experimentally in two-hit models of established pneumonia and mechanical ventilation [190].

How suitable are the models for testing the efficacy of new drugs in lung infections/pneumonia?

Testing new therapeutic approaches (antibiotics, adjunctive therapies) requires meaningful experimental protocols that match the clinical setting as closely as possible. Determining the efficiency of new treatments requires meaningful end-points. Measuring survival may be an appropriate end-point. This approach needs frequent monitoring following an approved scoring system with predefined humane end-points. Other end-points (e.g. lung permeability, inflammation, bacterial load) may be more appropriate for specific therapeutic approaches. Experimental *in vivo* studies have provided the rationale for approval of numerous antimicrobial therapies [191]. Others studies revealed significant disparities between *in vitro* and *in vivo* activity of antimicrobial compounds [192].

Detailed information regarding pulmonary infection is available in the supplementary material.

Task force statement

- Pneumonia phenotypes are diverse, largely depending on the pathogen, serotype and delivery route as well as host-specific factors.
- Understanding this diversity allows experimental modelling of different clinically relevant phenotypes.

Recommendations for experimental research in respiratory diseases

- Meaningful experimental protocols with clearly defined end-points should be used to study new treatments in pneumonia models.

Acute lung injury***How do we define ALI/ARDS for experimental research?***

ARDS is a syndrome caused by different triggers such as pneumonia, acid aspiration, sepsis or polytrauma. It is diagnosed by sudden onset, bilateral infiltrates, oedema not fully explained by cardiac failure or fluid overload and hypoxaemia (P_{aO_2}/F_{iO_2} ratio <300 mmHg) [193]. The American Thoracic Society workshop on ARDS recommended that animal models should meet at least three of the following four criteria: histologically defined tissue injury, alterations of the alveolo-capillary barrier, an inflammatory response and physiological dysfunction [194]. This definition is largely based on the assumption that the prime problem in ARDS is an acute inflammation-triggered increase in endothelial and epithelial permeability. Within this definition, models with pulmonary inflammation, but without hypoxaemia, are valid ARDS models. Models with hypoxaemia allow grading of disease severity, similar to the clinical grading, into mild, moderate or severe ARDS. Intensive care unit (ICU) treatments are life-saving for ARDS patients, but are probably also risk factors since their modification (mechanical ventilation [195], positioning [196]) improves survival. Hence, ICU treatments may contribute to the pathogenesis of ARDS and should be included in ARDS models [197–199].

What are the major unmet needs for modelling and studying ALI/ARDS?

Mortality of severe ARDS within the first week is 20% and 40% after 4 weeks [200]. Yet, most animal models last only a few hours. In many of the commonly used models (e.g. lipopolysaccharide or acid administration), animals surviving the first 72 h will recover completely [201]. The reason why 25–50% of patients will not recover is one of the central unresolved questions in ARDS [202]. Another important issue is that ARDS patients usually do not die of respiratory failure alone, but mostly succumb to multiple organ failure [203]. Therefore, ARDS models need to put more emphasis on extrapulmonary organ injury. Usual end-points in ARDS clinical trials, such as 28-day mortality, ventilator or ICU free-days are unrealistic for animal models. Unfortunately, there are no accepted surrogate end-points; even arterial oxygenation may be misleading [195]. Inflammation *per se* should be interpreted with caution, because inflammation develops easily and is frequently benign. End-points with absolute scales (e.g. oxygenation, compliance or wet-to-dry ratio) have benefits and allow better comparability between studies.

How can we model specific subgroups of ALI/ARDS?

Since a molecular signature is not available, a majority of ARDS models aim to replicate its aetiology and, in a minority, its pathophysiology (table 13). There are numerous reviews on assets and shortcomings of

TABLE 13 Animal models replicate acute respiratory distress syndrome (ARDS) aetiology or pathophysiology

	Risk factor %	Animal model	All animals % (2003–2007, n=1441)	All large animals % (2005–2016, n=341)	Large animals ≥12h % (n=63)
Aetiology					
Pneumonia	59	Pneumonia	Not specified	5	14
Extrapulmonary sepsis	16	Live bacteria	16	0	0
		LPS	19	12	13
		CLP	4	0	0
Aspiration	14	Acid aspiration	3	2	0
Inhalation and/or burn	2.6	Smoke and burn	0	29	49
Other	22	Various	0	10	2
ICU treatment					
Ventilation		Injurious ventilation	30	8	6
Hyperoxia		Hyperoxia	12	1	0
Pathophysiology					
		Bleomycin	10	0	0
		Lung lavage	0	17	6
		Oleic acid	5	13	3

For references listed in the table please refer to the supplementary material. The table provides an overview over the clinical risk factors for ARDS [S445, S446]. CLP: coecal ligation and puncture; LPS: lipopolysaccharide; ICU: intensive care unit. Other: blood transfusion, non-cardiogenic shock, downing, pulmonary vasculitis, contusion, polytrauma, drug overdose.

ARDS models [198, 199, 204–207]. Clinically, ARDS has been divided into pulmonary (direct) and non-pulmonary [208]. Experimentally, direct ARDS can be modelled by administering agents such as lipopolysaccharide, acid, smoke or bacteria into the airways. Non-pulmonary ARDS is more difficult to model, because systemic sepsis or peritonitis cause only relatively mild lung injury in laboratory animals. In the clinical course of sepsis, ARDS does usually not occur before several days, and it is therefore no surprise that short term sepsis models (*i.p.* or *i.v.* injection of bacteria or lipopolysaccharide) do not lead to severe lung injury.

How suitable are these models for testing and validating the efficacy of new drugs?

Of more than 150 ARDS trials, only two interventions have proven effective by sufficiently powered trials: low tidal volume ventilation and prone positioning [209]. While these two interventions were based on animal experiments, no single model can be accredited for this success. The lack of approved pharmacological interventions, despite so many promising preclinical trials, suggests major deficiencies of current ARDS models. One key problem is certainly that most experimental studies in rodents are short-term and use prophylactic rather than therapeutic interventions. Whether fully instrumented large animal models lasting beyond 24 h have a better predictive value for subsequent clinical translation remains to be shown.

Task force statement

- Current preclinical models of ALI or ARDS substantially deviate from the time course, management, and end-points of clinical ARDS.
- While lung inflammation is usually present, it is not identical to ALI or ARDS.
- There is at present no ideal model that recapitulates all features of ARDS; however, individual models reflect specific aspects of the disease.

Recommendations for experimental research in respiratory diseases

- The use of end-points on absolute scales is encouraged to facilitate assessment of disease severity and comparisons between studies.

Pulmonary hypertension

How do we define pulmonary hypertension for experimental research?

The pathogenesis of pulmonary hypertension involves a complex and multifactorial process [210–213]. The extensive remodelling of the pulmonary vasculature develops sequentially and includes medial hypertrophy, intimal proliferation, *in situ* thrombosis, occlusion of small vessels, loss of distal vessels and

the formation of plexiform lesions. Model systems that mimic part of the pathophysiological process of pulmonary hypertension are valuable for validating new targets or treatments and give insights into disease mechanisms (table 14). However, they do not recapitulate the full spectrum of the human condition. An ideal model of pulmonary hypertension would have a similar genetic basis, anatomy and physiology, involve the same underlying mechanisms, present similar phenotypes as do patients, and should help to predict the clinical efficacy of drugs. It is crucial to define the research problem as precisely as possible and to identify the strengths and weaknesses of each current available pulmonary hypertension model in the research context. Inherent limitations of the current available animal models are critically evaluated elsewhere [214–216].

What are the major unmet needs for modelling and studying pulmonary hypertension?

Animal pulmonary hypertension models should include a minimum of standard parameters to inform about important aspects of this complex disorder. Cardiac catheterisation is the gold standard to measure the following haemodynamic parameters *in vivo*: mean pulmonary artery pressure (or right ventricular (RV) systolic pressure for mice), systemic blood pressure and cardiac output. In addition to these parameters, RV hypertrophy should be assessed by the Fulton index and lung histology should be performed to evaluate wall thickness and the percentage of muscularised pulmonary arteries. Other secondary parameters (heart rate, RV pressure rise (dP/dt maximum) and fall (dP/dt minimum), right atrial pressure, RV end-diastolic pressure) and noninvasive techniques (echocardiography, cardiac computed tomography, magnetic resonance imaging, lung function and exercise tests) can be useful to add.

Since each model system is different and mimics only some parts of pulmonary hypertension, the association of several models combined with evidence obtained from human blood, DNA, bronchoalveolar lavage, urine, and lung tissue is usually the most meaningful approach (table 14) [217]. In addition, the use of primary cultures of human pulmonary vascular cells, studied at early passages, is another valuable tool. A significant contribution to the identification of emerging molecular targets in PH has been made through genetically modified animals [218–221]. However, none of these have realistically reproduced the human disease. By combining *in situ* observations, animal models and *in vitro* studies, our knowledge of pulmonary hypertension pathogenesis will continue to increase [217].

How can we model specific subgroups of pulmonary hypertension (group 1, 2 and 3 pulmonary arterial hypertension)?

Although different forms of pulmonary hypertension [222] reflect distinct pathophysiological mechanisms, there are common denominators, such as endothelial dysfunction, exaggerated recruitment of inflammatory cells, imbalance between apoptotic and survival pathways, and abnormal interaction between endothelium and surrounding pulmonary vascular cells in pulmonary arteries [210–213]. Therefore, efforts should continue to better understand the chronobiology of the different pulmonary hypertension subgroups [223–228]. Specifically, models of pulmonary hypertension groups 2, 4 and 5 are needed, even though some common forms of pulmonary hypertension, such as chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with left heart disease or systemic sclerosis-related pulmonary hypertension have sporadically been modelled in animals [223, 225, 229, 230]. A better understanding of the similarities and differences between pulmonary hypertension subgroups is needed to know what models exist, how they can help to identify more adapted and more powerful therapeutic tools and to propose new and more relevant *in vivo*, *ex vivo* and *in vitro* models.

How suitable are these models for testing and validating the efficacy of new drugs?

A key element in translational research is the development of biomarkers for disease diagnosis, progression, and for testing efficacy of innovative agents. Despite drug development success in recent years, the failure to translate positive results from preclinical pulmonary hypertension studies into clinical therapies remains a major problem [217]. Both curative and preventive protocols are useful to validate clinical relevance of potential targets and to understand their mechanisms of action [231]. In confirmatory investigations, more stringent study designs are recommended and the addition of complementary models is essential.

Task force statement

- Animal models used in pulmonary hypertension research are very valuable for validating new molecular targets and/or treatments and giving insights into pathogenic mechanisms.
- No ideal model recapitulates all features of pulmonary hypertension; however, it is clear that by combining *in situ* observations together with findings in animals and *in vitro*, our knowledge of the pathobiology of pulmonary hypertension will continue to accelerate.

TABLE 14 Pulmonary arterial hypertension (PAH): a review from the literature of the different multi-model combination systems used to study a specific aspect of pulmonary hypertension (PH) pathogenesis

Area of research	Main focus	Main experimental tools used	References
Genetic factors	Genetic studies	Genomic DNA sample and/or microdissected cell DNA and matching clinical features of discovery and validation cohorts Genome/exome seq and functional studies Induced pluripotent stem cells (iPSCs) combined with next generation sequencing	[S447–S453] [S454, S455] Related review: [S456]
	Role of a specific gene mutation: <i>i.e.</i> BMPR2, BMPR1B, ACVRL1, ENG, SMAD9, CAV, TBX4, NOTCH3 or KCNK3 mutation	Genomic DNA sample and/or microdissected cell DNA and matching clinical data DNA-Seq, RNA-Seq, functional studies	[S447, S449, S451, S453, S457–S477]
	Epigenetic	Methyl-Seq, and/or methyl-DNA immune precipitation chips <i>In vivo</i> models in rodents and/or <i>in vitro</i> cell culture models	[S478–S493]
	Polymorphisms	DNA sample with matching clinical data and functional studies	[S494–S544]
Environmental factors	Hypoxia (acute, chronic or intermittent hypoxia exposure)	<i>In vivo</i> model(s) in rodents and larger mammals, and/or <i>in vitro</i> cell culture models, and/or analyses of human samples from patients from the group 3 of the current clinical classification of PH and/or human samples from healthy subjects or patients exposed to high altitude	Selection of related reviews: [S545–S648]
	Drugs and toxins	<i>In vivo</i> model(s) in rodents and larger mammals, and/or <i>in vitro</i> cell culture models, and/or pharmacovigilance programme	Selection of related reviews: [S649–S675]
	Lifestyle factors (nutrition, tobacco use, physical activity, etc.)	<i>In vivo</i> model(s) in rodents and/or larger mammals, and/or epidemiological study	Selection of related reviews: [S673, S676–S716]
	Infectious agents	<i>In vivo</i> model(s) in rodents (schistosomiasis) and larger mammals, and/or <i>in vitro</i> cell culture models	Selection of related reviews: [S712, S717–S755]
Pulmonary endothelial dysfunction	Production of vasoreactive mediators	<i>In vivo</i> model(s) in rodents (MCT model, Su5416+hypoxia models or aortic banding model) and/or larger mammals	Selection of related reviews: [S663, S756–S818]
	Phenotypic alterations of pulmonary endothelial cells: enhanced proliferation, resistance to apoptosis and pro-inflammatory state	<i>In vitro</i> cell culture models Analyses of human samples	
	Production of activators and inhibitors of smooth muscle cell growth and migration	Su5416+hypoxia model and <i>in vitro</i> cell culture models	
	Production of prothrombotic and antithrombotic mediators	MCT model, BMPR2 deficient animals Endothelial-targeted, fas-induced apoptosis (FIA) transgenic mice	
	Production of proinflammatory signals		
Smooth muscle hyperplasia	Barrier function		Selection of related reviews: [S584, S590, S761, S775, S791, S794, S802, S819–851]
	Regulation of endothelial cell differentiation and specification		
	Balance between proliferation and apoptosis	<i>In vivo</i> model(s) in rodents and larger mammals, and/or <i>in vitro</i> cell culture models	
	Properties of smooth muscle hyperpolarisation and relaxation	Analyses of human samples from PAH patients and/or human samples from healthy subjects or patients exposed to high altitude	
	Deregulations of cellular energetics		
Plexogenic pulmonary vascular lesions	Smooth muscle cell differentiation	MCT model, BMPR2 deficient animals	[S475, S852–S863]
	Ion channels and membrane potential	Analyses of human samples from PAH patients	
		Su5416+hypoxia hypoxia model, Su5416+ pneumonectomy model	

Continued

TABLE 14 Continued

Area of research	Main focus	Main experimental tools used	References
Adventitial fibrosis	Phenotypic alterations of adventitial fibroblasts: enhanced proliferation, resistance to apoptosis and pro-inflammatory and profibrotic states Secretion of mediators	<i>In vivo</i> model(s) in rodents and larger mammals, and/or <i>in vitro</i> cell culture models Analyses of human samples from PAH patients and/or human samples from healthy subjects or patients exposed to high altitude	Selection of related reviews: [S556, S589, S599, S617, S783, S864–869]
Metabolism dysregulation	Shift from glycolytic to oxidative metabolism Mitochondrial alterations Fatty acid metabolism	Analyses of human samples from PAH patients and/or human samples from healthy subjects and/or <i>in vivo</i> imaging <i>In vivo</i> model(s) in rodents and larger mammals, and/or <i>in vitro</i> cell culture models	Selection of related reviews: [S556, S840, S870–S874]
<i>In situ</i> thrombosis	Blood coagulation and fibrinolysis Platelet biology Histological analyses	Analyses of human samples from PAH patients and/or human samples from healthy subjects <i>In vivo</i> model(s) in rodents and larger mammals	Selection of related reviews: [S765, S875–S892]
Inflammation and dysimmunity	Cytokine/chemokine secretion and roles Immune cell infiltration Autoimmunity Lymphoid neogenesis	Rat models of MCT, mouse models of chronic hypoxia Rat models of MCT, Su5416+hypoxia, Su-ovalbumin, or aortic banding Rat models of MCT, Su5416+hypoxia, Su5416+ovalbumin Rat models of MCT, Su5416+hypoxia, Su5416+ovalbumin	Selection of related reviews: [S558, S617, S620, S758, S763, S766, S775, S893–S923]

For references listed in the table please refer to the supplementary material.

Recommendations for experimental research in respiratory diseases

- There is a need for robust assessments of the degree of pulmonary hypertension severity in animal models to confirm establishment of experimental pulmonary hypertension before studying it and/or modulating it.
- The survival rate, the time schedule and the reasons for the animal model choice have to be indicated and justified.
- A better understanding of the similarities and differences between pulmonary hypertension groups 1, 2, 4 and 5 is needed.

Conclusion

This task force statement summarises key elements of the current state in modelling lung disease using animals, tissues and cell cultures. The effort of many generations of scientists and the sacrifice of countless laboratory animals has increased our knowledge of lung health and disease enormously. One must, however, not deny the presence of failures in experimental research, notably the optimistic nature of researchers as they strive to translate biology from animal models to humans, which may lead to a number of possible biases that may misinform the outcomes. The task force emphasises the need for scientists and physicians to have an accurate and complete knowledge of the available models. The task force highlights the importance of standard operating procedures, data quality and research repositories in order to ensure that the experimental conditions are always rigorously described, ensuring their repeatability for other groups. It is of particular relevance to acknowledge the specific benefits and limitations of experimental models and, in most instances, avoid claiming to have “The Best Model of Disease X”. This will result in the more efficient use of resources, reduction in the numbers of animals, and will permit enhancement of the ethical standards of experimental pulmonary research. It is crucial to utilise the complementarity between *in vivo*, *ex vivo* and *in vitro* models to translate experimental findings to human disease. The scientific community has to acknowledge that major breakthroughs in experimental research do not guarantee successful translation to humans.

An important future task is to facilitate and increase the availability of human tissues. Sharing data from patient cohorts (clinical data, samples, “omics”, *etc.*) in order to compare and translate results from models to human tissue, as well as between research groups, is instrumental if we want to do better. This process requires the support of patients to contribute to this challenging research field.

Acknowledgements: We thank Thomy Tonia and David Rigau, ERS methodologists, for their help with the methodological overview, Valérie Vaccaro for organising the task force meetings, and François Daubeuf (Laboratoire d’Innovation Thérapeutique, Université de Strasbourg, France) for his help with the section on asthma. We thank also OrphaLung and the Filière de santé des maladies respiratoires rares RespiFIL, CRISALIS F-CRIN French network for severe asthma, ANR-11-BSV-011-01 meso-IPF, ANR-16-CE14-0004-01 SHOT-IPF and Investissement d’Avenir ANR-11-LABX-0021-01-LipSTIC LabEx, LABEX ANR-10-LABX-0034_Medialis.

Conflict of interest: P. Bonniaud reports personal fees (board/advice) from Roche, Boehringer, Novartis, TEVA and AstraZeneca, and travel reimbursement (ERS meetings) from Chiesi, outside the submitted work. A. Fabre reports grants from Pfizer, reagents from Roche, and personal fees from MSD (Merck Sharp & Dohme Corp.), outside the submitted work. T. Maes reports grants from Belgian Science Policy (Federal Government Belgium-Interuniversity attraction Poles), Ghent University (Concerted Research Action and Spearhead Immunology) and Novartis, and personal fees (GSK Clinical Science award: prize for best abstract presentation at Belgian Pulmonology Society Meeting 2015) and non-financial support (travel/accommodation/meeting expenses) from GlaxoSmithKline, outside the submitted work; and is shareholder of Oryzon Genomics. W. Shi reports grants from National Institute of Health and Department of Defense, outside the submitted work. M. Stampfli reports grants from RespiVert and MedImmune, and personal fees from AstraZeneca and Boehringer Ingelheim, outside the submitted work. S. Uhlig reports grants from Germany Research Foundation (DFG), during the conduct of the study. E. White reports grants and other support from NIH, personal fees for consulting from Akcea Therapeutics and Kadmon Pharmaceuticals, and research grants and personal fees for consulting from Boehringer-Ingelheim, outside the submitted work. M. Witzenzrath reports grants and personal fees from Bayer Health Care, Boehringer Ingelheim, Biotest and Vaxxilon, and personal fees from Actelion, Berlin Chemie, AstraZeneca, GlaxoSmithKline and Novartis, outside the submitted work. B. Crestani has received an honorarium for speaking from Aventis, honoraria for speaking, grants for research and congress travel support grants from Boehringer Ingelheim and Roche, grants for research from CARDIF and LVL, an honorarium for speaking and congress travel support from AstraZeneca, and a grant for research and congress travel support from MedImmune, outside the submitted work. O. Eickelberg reports grants from the Helmholtz Association, the German Center of Lung Research, Roche, and Bayer and consultancy/lecture fees from BMS, Novartis, Bayer, Intermune, McKinsey, and MorphoSys. A. Guenther reports research funding, and compensation for lectures and consulting from Roche, compensation for lectures and consulting from Boehringer Ingelheim and Teva, and research funding from Sanofi, outside the submitted work. G. Jenkins reports grants from GlaxoSmithKline (institutional funding for the PROFILE study) and the Medical Research Council (co-funder of the PROFILE study with GSK through MICA award), during the conduct of the study; grants from Biogen (SRA for work on integrins in IPF), personal fees (consulting and data monitoring committees on lung fibrosis) from Boehringer Ingelheim, grants (PhD studentship) from Galecto, personal fees (advisory board on IPF) from GlaxoSmithKline and Intermune, grants and personal fees (consulting on IPF, PhD studentship) from MedImmune, personal fees (consulting on IPF) from PharmAkea, personal fees (advisory board on IPF and lecture fees) from Roche, consulting on IPF (with no payment received to date) for Pliant Therapeutics, participating in scientific advisory boards (with no payment received to date) for NuMedii, and personal fees from Pulmatrix, outside the submitted work; and is a trustee for the charities Action for Pulmonary Fibrosis and the British Thoracic Society. G. Joos reports grants, personal fees and non-financial support from AstraZeneca, grants and personal fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline and Novartis, and personal fees from Mundipharma, Sandoz and Teva, outside the submitted work. U.A. Maus reports grants from Federal Ministry of Education and Research, German Research Foundation and Lower Saxony Society for the Control of Tuberculosis and Bronchial Diseases, outside the submitted work. L. Richeldi reports grants and personal fees (for advisory board membership) from Intermune, personal fees (for advisory board membership) from MedImmune, Roche and FibroGen, personal fees (for consulting activity) from Biogen, Sanofi-Aventis, ImmuneWorks, Celgene and Nitto, personal fees (for speaking) from Shionogi, and personal fees (for membership of steering committee) from Boehringer Ingelheim, outside the submitted work. M. Kolb reports grants and personal fees from Roche, Boehringer Ingelheim, GSK, Gilead, Prometic and Alkermes, grants from Actelion, Respivert and Synairgen, and personal fees from AstraZeneca and Genoa, outside the submitted work.

References

- 1 Wadman M. Animal rights: Chimpanzee research on trial. *Nature* 2011; 474: 268–271.
- 2 Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. *Official Journal of the European Union* 2010; 276: 33–79.
- 3 Keiser NW, Engelhardt JF. New animal models of cystic fibrosis: what are they teaching us? *Curr Opin Pulm Med* 2011; 17: 478–483.
- 4 Ask K, Labiris R, Farkas L, *et al.* Comparison between conventional and “clinical” assessment of experimental lung fibrosis. *J Transl Med* 2008; 6: 16.
- 5 Moeller A, Ask K, Warburton D, *et al.* The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? *Int J Biochem Cell Biol* 2008; 40: 362–382.
- 6 Trist DG. Scientific process, pharmacology and drug discovery. *Curr Opin Pharmacol* 2011; 11: 528–533.
- 7 Kilkenny C, Browne WJ, Cuthill IC, *et al.* Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. *PLoS Biol* 2010; 8: e1000412.
- 8 Franco NH, Correia-Neves M, Olsson IA. Animal welfare in studies on murine tuberculosis: assessing progress over a 12-year period and the need for further improvement. *PLoS One* 2012; 7: e47723.
- 9 van der Worp HB, Howells DW, Sena ES, *et al.* Can animal models of disease reliably inform human studies? *PLoS Med* 2010; 7: e1000245.

- 10 Herzberg N. Mice losing their allure as experimental subjects to study human disease. *The Guardian*, March 20 2015. Available at www.theguardian.com/science/2015/mar/20/mice-clinical-trials-human-disease
- 11 Ohno Y. ICH guidelines—implementation of the 3Rs (refinement, reduction, and replacement): incorporating best scientific practices into the regulatory process. *ILAR J* 2002; 43: Suppl., S95–S98.
- 12 Kilkenny C, Parsons N, Kadyszewski E, *et al.* Survey of the quality of experimental design, statistical analysis and reporting of research using animals. *PLoS One* 2009; 4: e7824.
- 13 Gammon ST, Foje N, Brewer EM, *et al.* Preclinical anatomical, molecular, and functional imaging of the lung with multiple modalities. *Am J Physiol Lung Cell Mol Physiol* 2014; 306: L897–L914.
- 14 Nelson M, Naismith DJ, Burley V, *et al.* Nutrient intakes, vitamin-mineral supplementation, and intelligence in British schoolchildren. *Br J Nutr* 1990; 64: 13–22.
- 15 Mercer PF, Abbott-Banner K, Adcock IM, *et al.* Translational models of lung disease. *Clin Sci* 2015; 128: 235–256.
- 16 Weibel ER. Lung morphometry: the link between structure and function. *Cell Tissue Res* 2017; 367: 413–426.
- 17 Hsia CC, Hyde DM, Ochs M, *et al.* An official research policy statement of the American Thoracic Society/ European Respiratory Society: standards for quantitative assessment of lung structure. *Am J Respir Crit Care Med* 2010; 181: 394–418.
- 18 Uhlig S, Yang Y, Waade J, *et al.* Differential regulation of lung endothelial permeability in vitro and in situ. *Cell Physiol Biochem* 2014; 34: 1–19.
- 19 Discher DE, Janmey P, Wang YL. Tissue cells feel and respond to the stiffness of their substrate. *Science* 2005; 310: 1139–1143.
- 20 Marenzana M, Vande Velde G. Refine, reduce, replace: Imaging of fibrosis and arthritis in animal models. *Best Pract Res Clin Rheumatol* 2015; 29: 715–740.
- 21 International Mouse Phenotyping Consortium. Produce and phenotype knockout mouse lines for 20,000 genes. www.mousephenotype.org Date last accessed: 2017.
- 22 Gentile LF, Nacionales DC, Lopez MC, *et al.* A better understanding of why murine models of trauma do not recapitulate the human syndrome. *Crit Care Med* 2014; 42: 1406–1413.
- 23 Gras D, Bourdin A, Vachier I, *et al.* An *ex vivo* model of severe asthma using reconstituted human bronchial epithelium. *J Allergy Clin Immunol* 2012; 129: 1259–1266.
- 24 Burgstaller G, Vierkotten S, Lindner M, *et al.* Multidimensional immunolabeling and 4D time-lapse imaging of vital *ex vivo* lung tissue. *Am J Physiol Lung Cell Mol Physiol* 2015; 309: L323–L332.
- 25 Committee on Models for Biomedical Research, Board on Basic Biology, Commission on Life Sciences, National Research Council. Appendix C, Models for Biomedical Research A New Perspective. Biomedical Models and Resources: Current Needs and Future Opportunities. Washington, National Academies Press (US), 1998. Available from www.ncbi.nlm.nih.gov/books/NBK230278/
- 26 Rackley CR, Stripp BR. Building and maintaining the epithelium of the lung. *J Clin Invest* 2012; 122: 2724–2730.
- 27 Balestrini JL, Gard AL, Gerhold KA, *et al.* Comparative biology of decellularized lung matrix: Implications of species mismatch in regenerative medicine. *Biomaterials* 2016; 102: 220–230.
- 28 Kirschvink N, Reinhold P. Use of alternative animals as asthma models. *Curr Drug Targets* 2008; 9: 470–484.
- 29 Irusen EM (ed). Lung Diseases - Selected State of the Art Reviews. London, InTech, 2012.
- 30 Bonfield TL. In vivo models of lung disease. In: Irusen EM (ed). Lung Diseases - Selected State of the Art Reviews. London, InTech, 2012.
- 31 Mahavadi P, Korfei M, Henneke I, *et al.* Epithelial stress and apoptosis underlie Hermansky-Pudlak syndrome-associated interstitial pneumonia. *Am J Respir Crit Care Med* 2010; 182: 207–219.
- 32 Besnard V, Matsuzaki Y, Clark J, *et al.* Conditional deletion of Abca3 in alveolar type II cells alters surfactant homeostasis in newborn and adult mice. *Am J Physiol Lung Cell Mol Physiol* 2010; 298: L646–L659.
- 33 Reiner CR. Advances in the understanding of pathogenesis, and diagnostics and therapeutics for feline allergic asthma. *Vet J* 2011; 190: 28–33.
- 34 Naeije R. Pulmonary circulation at high altitude. *Respiration* 1997; 64: 429–434.
- 35 Holt TN, Callan RJ. Pulmonary arterial pressure testing for high mountain disease in cattle. *Vet Clin N Am Food Anim Pract* 2007; 23: 575–596.
- 36 Heikkila-Laurila HP, Rajamaki MM. Idiopathic pulmonary fibrosis in West Highland white terriers. *Vet Clin N Am Small Anim Pract* 2014; 44: 129–142.
- 37 Williams K, Malarkey D, Cohn L, *et al.* Identification of spontaneous feline idiopathic pulmonary fibrosis: morphology and ultrastructural evidence for a type II pneumocyte defect. *Chest* 2004; 125: 2278–2288.
- 38 Cohn LA, Norris CR, Hawkins EC, *et al.* Identification and characterization of an idiopathic pulmonary fibrosis-like condition in cats. *J Vet Intern Med* 2004; 18: 632–641.
- 39 National Heart, Lung, and Blood Institute. FY 2017 Funding and Operating Guidelines. Bethesda, National Institutes of Health, 2017. Available from www.nhlbi.nih.gov/research/funding/general/current-operating-guidelines
- 40 Kling M. A review of respiratory system anatomy, physiology, and disease in mice, rat, hamster and gerbil. *Vet Clin North Am Exot Anim Pract* 2011; 2: 287–337.
- 41 Thiesse J, Namati E, Sieren JC, *et al.* Lung structure phenotype variation in inbred mouse strains revealed through in vivo micro-CT imaging. *J Appl Physiol* 2010; 109: 1960–1968.
- 42 Zschaler J, Schlorke D, Arnhold J. Differences in innate immune response between man and mouse. *Crit Rev Immunol* 2014; 34: 433–454.
- 43 Decologne N, Kolb M, Margetts PJ, *et al.* TGF-beta1 induces progressive pleural scarring and subpleural fibrosis. *J Immunol* 2007; 179: 6043–6051.
- 44 Martic-Kehl MI, Schibli R, Schubiger PA. Can animal data predict human outcome? Problems and pitfalls of translational animal research. *Eur J Nucl Med Mol Imaging* 2012; 39: 1492–1496.
- 45 Vaughan L, Glanzel W, Korch C, *et al.* Widespread use of misidentified cell line KB (HeLa): incorrect attribution and its impact revealed through mining the scientific literature. *Cancer Res* 2017; 77: 2784–2788.
- 46 Durr E, Yu J, Krasinska KM, *et al.* Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. *Nat Biotechnol* 2004; 22: 985–992.

- 47 Gonzalez R, Yang YH, Griffin C, *et al.* Freshly isolated rat alveolar type I cells, type II cells, and cultured type II cells have distinct molecular phenotypes. *Am J Physiol Lung Cell Mol Physiol* 2005; 288: L179–L189.
- 48 Xu Y, Mizuno T, Sridharan A, *et al.* Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis. *JCI insight* 2016; 1: e90558.
- 49 Mulugeta S, Nureki S, Beers MF. Lost after translation: insights from pulmonary surfactant for understanding the role of alveolar epithelial dysfunction and cellular quality control in fibrotic lung disease. *Am J Physiol Lung Cell Mol Physiol* 2015; 309: L507–L525.
- 50 Thomas AQ, Carneal J, Markin C, *et al.* Specific bone morphogenic protein receptor II mutations found in primary pulmonary hypertension cause different biochemical phenotypes in vitro. *Chest* 2002; 121: Suppl. 3, 83S.
- 51 Garg N, Wang M, Hyde E, *et al.* Three-dimensional microbiome and metabolome cartography of a diseased human lung. *Cell Host Microbe* 2017; 22: 705–716 e704.
- 52 Feng G, Mellor RH, Bernstein M, *et al.* Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. *Neuron* 2000; 28: 41–51.
- 53 Tasic B, Hippenmeyer S, Wang C, *et al.* Site-specific integrase-mediated transgenesis in mice via pronuclear injection. *Proc Natl Acad Sci USA* 2011; 108: 7902–7907.
- 54 Kwan KM. Conditional alleles in mice: practical considerations for tissue-specific knockouts. *Genesis* 2002; 32: 49–62.
- 55 Zhang W, Menke DB, Jiang M, *et al.* Spatial-temporal targeting of lung-specific mesenchyme by a Tbx4 enhancer. *BMC Biol* 2013; 11: 111.
- 56 Perl AK, Zhang L, Whitsett JA. Conditional expression of genes in the respiratory epithelium in transgenic mice: cautionary notes and toward building a better mouse trap. *Am J Respir Cell Mol Biol* 2009; 40: 1–3.
- 57 Smith RW, Hicks DA, Reynolds SD. Roles for β -catenin and doxycycline in the regulation of respiratory epithelial cell frequency and function. *Am J Respir Cell Mol Biol* 2012; 46: 115–124.
- 58 Rawlins EL, Perl AK. The a'MAZE'ing world of lung-specific transgenic mice. *Am J Respir Cell Mol Biol* 2012; 46: 269–282.
- 59 Sisson TH, Hansen JM, Shah M, *et al.* Expression of the reverse tetracycline-transactivator gene causes emphysema-like changes in mice. *Am J Respir Cell Mol Biol* 2006; 34: 552–560.
- 60 Müller-Quernheim J. MMPs are regulatory enzymes in pathways of inflammatory disorders, tissue injury, malignancies and remodelling of the lung. *Eur Respir J* 2011; 38: 12–14.
- 61 Vieillard-Baron A, Frisdal E, Eddahibi S, *et al.* Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats. *Circ Res* 2000; 87: 418–425.
- 62 Ren S, Guo LL, Yang J, *et al.* Doxycycline attenuates acrolein-induced mucin production, in part by inhibiting MMP-9. *Eur J Pharmacol* 2011; 650: 418–423.
- 63 Moon A, Gil S, Gill SE, *et al.* Doxycycline impairs neutrophil migration to the airspaces of the lung in mice exposed to intratracheal lipopolysaccharide. *J Inflamm (Lond)* 2012; 9: 31.
- 64 Wang Z, Klipfell E, Bennett BJ, *et al.* Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* 2011; 472: 57–63.
- 65 Drakes M, Blanchard T, Czinn S. Bacterial probiotic modulation of dendritic cells. *Infect Immun* 2004; 72: 3299–3309.
- 66 Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. *Dev Biol* 2002; 244: 305–318.
- 67 Wirth A, Benyó Z, Lukasova M, *et al.* G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. *Nat Med* 2008; 14: 64–68.
- 68 Koitabashi N, Bedja D, Zaiman AL, *et al.* Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. *Circ Res* 2009; 105: 12–15.
- 69 Thyagarajan B, Guimarães MJ, Groth AC, *et al.* Mammalian genomes contain active recombinase recognition sites. *Gene* 2000; 244: 47–54.
- 70 Schmidt EE, Taylor DS, Prigge JR, *et al.* Illegitimate Cre-dependent chromosome rearrangements in transgenic mouse spermatids. *Proc Natl Acad Sci U S A* 2000; 97: 13702–13707.
- 71 Lomeli H, Ramos-Mejía V, Gertsenstein M, *et al.* Targeted insertion of Cre recombinase into the TNAP gene: excision in primordial germ cells. *Genesis* 2000; 26: 116–117.
- 72 Rassoulzadegan M, Grandjean V, Gounon P, *et al.* RNA-mediated non-mendelian inheritance of an epigenetic change in the mouse. *Nature* 2006; 441: 469–474.
- 73 Ramirez A, Page A, Gandarillas A, *et al.* A keratin K5Cre transgenic line appropriate for tissue-specific or generalized Cre-mediated recombination. *Genesis* 2004; 39: 52–57.
- 74 de Lange WJ, Halabi CM, Beyer AM, *et al.* Germ line activation of the Tie2 and SMMHC promoters causes noncell-specific deletion of floxed alleles. *Physiol Genomics* 2008; 35: 1–4.
- 75 Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. *Nat Biotechnol* 2014; 32: 347–355.
- 76 Tsai SQ, Wyvekens N, Khayter C, *et al.* Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. *Nat Biotechnol* 2014; 32: 569–576.
- 77 Ran FA, Hsu PD, Lin CY, *et al.* Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. *Cell* 2013; 154: 1380–1389.
- 78 Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention: updated 2016. Available from www.ginasthma.org
- 79 Eder W, Ege MJ, von Mutius E. The asthma epidemic. *N Engl J Med* 2006; 355: 2226–2235.
- 80 Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. *Nat Med* 2012; 18: 716–725.
- 81 Lotvall J, Akdis CA, Bacharier LB, *et al.* Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. *J Allergy Clin Immunol* 2011; 127: 355–360.
- 82 Daubeuf F, Hachet-Haas M, Gizzi P, *et al.* An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in mice. *J Biol Chem* 2013; 288: 11865–11876.
- 83 Nials AT, Uddin S. Mouse models of allergic asthma: acute and chronic allergen challenge. *Dis Model Mech* 2008; 1: 213–220.

- 84 Chung KF, Wenzel SE, Brozek JL, *et al.* International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J* 2014; 43: 343–373.
- 85 Wenzel S, Holgate ST. The mouse trap: It still yields few answers in asthma. *Am J Respir Crit Care Med* 2006; 174: 1173–1176.
- 86 Maes T, Joos GF, Brusselle GG. Targeting interleukin-4 in asthma: lost in translation? *Am J Respir Cell Mol Biol* 2012; 47: 261–270.
- 87 Hirota JA, Ask K, Fritz D, *et al.* Role of STAT6 and SMAD2 in a model of chronic allergen exposure: a mouse strain comparison study. *Clin Exp Allergy* 2009; 39: 147–158.
- 88 Kelada SN, Wilson MS, Tavarez U, *et al.* Strain-dependent genomic factors affect allergen-induced airway hyperresponsiveness in mice. *Am J Respir Cell Mol Biol* 2011; 45: 817–824.
- 89 Shinagawa K, Kojima M. Mouse model of airway remodeling: strain differences. *Am J Respir Crit Care Med* 2003; 168: 959–967.
- 90 Wegmann M, Fehrenbach H, Fehrenbach A, *et al.* Involvement of distal airways in a chronic model of experimental asthma. *Clin Exp Allergy* 2005; 35: 1263–1271.
- 91 Fattouh R, Midence NG, Arias K, *et al.* Transforming growth factor-beta regulates house dust mite-induced allergic airway inflammation but not airway remodeling. *Am J Respir Crit Care Med* 2008; 177: 593–603.
- 92 Chesne J, Braza F, Chadeuf G, *et al.* Prime role of IL-17A in neutrophilia and airway smooth muscle contraction in a house dust mite-induced allergic asthma model. *J Allergy Clin Immunol* 2015; 135: 1643–1643.
- 93 Moerlose KB, Pauwels RA, Joos GF. Short-term cigarette smoke exposure enhances allergic airway inflammation in mice. *Am J Respir Crit Care Med* 2005; 172: 168–172.
- 94 Lanckacker EA, Tournoy KG, Hammad H, *et al.* Short cigarette smoke exposure facilitates sensitisation and asthma development in mice. *Eur Respir J* 2013; 41: 1189–1199.
- 95 Maes T, Provoost S, Lanckacker EA, *et al.* Mouse models to unravel the role of inhaled pollutants on allergic sensitization and airway inflammation. *Respir Res* 2010; 11: 7.
- 96 De Grove KC, Provoost S, Hendriks RW, *et al.* Dysregulation of type 2 innate lymphoid cells and TH2 cells impairs pollutant-induced allergic airway responses H2 cells impairs pollutant-induced allergic airway responses. *J Allergy Clin Immunol* 2017; 139: 246–257.
- 97 Brandt EB, Khurana Hershey GK. A combination of dexamethasone and anti-IL-17A treatment can alleviate diesel exhaust particle-induced steroid insensitive asthma. *J Allergy Clin Immunol* 2016; 138: 924–928.
- 98 Mahmutovic Persson I, Akbarshahi H, Menzel M, *et al.* Increased expression of upstream TH2-cytokines in a mouse model of viral-induced asthma exacerbation. *J Transl Med* 2016; 14: 52.
- 99 Ravanetti L, Dijkhuis A, Sabogal Pineros YS, *et al.* An early innate response underlies severe influenza-induced exacerbations of asthma in a novel steroid-insensitive and anti-IL-5-responsive mouse model. *Allergy* 2017; 72: 737–753.
- 100 Kim RY, Horvat JC, Pinkerton JW, *et al.* MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2. *J Allergy Clin Immunol* 2017; 139: 519–532.
- 101 Hadebe S, Kirstein F, Fierens K, *et al.* Microbial ligand costimulation drives neutrophilic steroid-refractory asthma. *PLoS One* 2015; 10: e0134219.
- 102 Eisenbarth SC, Piggott DA, Huleatt JW, *et al.* Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. *J Exp Med* 2002; 196: 1645–1651.
- 103 Schuijs MJ, Willart MA, Vergote K, *et al.* Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells. *Science* 2015; 349: 1106–1110.
- 104 Dinger K, Kasper P, Hucklenbruch-Rother E, *et al.* Early-onset obesity dysregulates pulmonary adipocytokine/insulin signaling and induces asthma-like disease in mice. *Sci Rep* 2016; 6: 24168.
- 105 Vital M, Harkema JR, Rizzo M, *et al.* Alterations of the murine gut microbiome with age and allergic airway disease. *J Immunol Res* 2015; 2015: 892568.
- 106 Aun MV, Bonamichi-Santos R, Arantes-Costa FM, *et al.* Animal models of asthma: utility and limitations. *J Asthma Allergy* 2017; 10: 293–301.
- 107 Bonvini SJ, Birrell MA, Grace MS, *et al.* Transient receptor potential cation channel, subfamily V, member 4 and airway sensory afferent activation: Role of adenosine triphosphate. *J Allergy Clin Immunol* 2016; 138: 249–261.
- 108 Kistemaker LE, Bos IS, Menzen MH, *et al.* Combination therapy of tiotropium and ciclesonide attenuates airway inflammation and remodeling in a guinea pig model of chronic asthma. *Respir Res* 2016; 17: 13.
- 109 Yu L, Liu Q, Canning BJ. Evidence for autocrine and paracrine regulation of allergen-induced mast cell mediator release in the guinea pig airways. *Eur J Pharmacol* 2018; 822: 108–118.
- 110 Freund-Michel V, Frossard N. Overexpression of functional TrkA receptors after internalisation in human airway smooth muscle cells. *Biochim Biophys Acta* 2008; 1783: 1964–1971.
- 111 Witzernath M, Ahrens B, Kube SM, *et al.* Detection of allergen-induced airway hyperresponsiveness in isolated mouse lungs. *Am J Physiol Lung Cell Mol Physiol* 2006; 291: L466–L472.
- 112 Flood-Page PT, Menzies-Gow AN, Kay AB, *et al.* Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. *Am J Respir Crit Care Med* 2003; 167: 199–204.
- 113 Yancey SW, Ortega HG, Keene ON, *et al.* Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. *J Allergy Clin Immunol* 2017; 139: 1167–1175.
- 114 Vestbo J, Hurd SS, Agusti AG, *et al.* Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2013; 187: 347–365.
- 115 Vestbo J, Edwards LD, Scanlon PD, *et al.* Changes in forced expiratory volume in 1 second over time in COPD. *N Engl J Med* 2011; 365: 1184–1192.
- 116 Lange P, Celli B, Agusti A, *et al.* Lung-function trajectories leading to chronic obstructive pulmonary disease. *N Engl J Med* 2015; 373: 111–122.
- 117 Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. *Lancet* 2015; 385: 899–909.
- 118 Woodruff PG, Barr RG, Bleecker E, *et al.* Clinical significance of symptoms in smokers with preserved pulmonary function. *N Engl J Med* 2016; 374: 1811–1821.

- 119 Jones B, Donovan C, Liu G, *et al.* Animal models of COPD: What do they tell us? *Respirology* 2017; 22: 21–32.
- 120 Ni K, Serban KA, Batra C, *et al.* Alpha-1 antitrypsin investigations using animal models of emphysema. *Ann Am Thorac Soc* 2016; 13: Suppl. 4, S311–S316.
- 121 Stevenson CS, Birrell MA. Moving towards a new generation of animal models for asthma and COPD with improved clinical relevance. *Pharmacol Ther* 2011; 130: 93–105.
- 122 Leberl M, Kratzer A, Taraseviciene-Stewart L. Tobacco smoke induced COPD/emphysema in the animal model—are we all on the same page? *Front Physiol* 2013; 4: 91.
- 123 Nikota JK, Stampfli MR. Cigarette smoke-induced inflammation and respiratory host defense: Insights from animal models. *Pulm Pharmacol Ther* 2012; 25: 257–262.
- 124 Shapiro SD. The use of transgenic mice for modeling airways disease. *Pulm Pharmacol Ther* 2008; 21: 699–701.
- 125 Shapiro SD. Animal models for chronic obstructive pulmonary disease: age of klotho and marlboro mice. *Am J Respir Cell Mol Biol* 2000; 22: 4–7.
- 126 Churg A, Sin DD, Wright JL. Everything prevents emphysema: are animal models of cigarette smoke-induced chronic obstructive pulmonary disease any use? *Am J Respir Cell Mol Biol* 2011; 45: 1111–1115.
- 127 Vlahos R, Bozinovski S. Preclinical murine models of chronic obstructive pulmonary disease. *Eur J Pharmacol* 2015; 759: 265–271.
- 128 Brusselle GG, Bracke KR, Maes T, *et al.* Murine models of COPD. *Pulm Pharmacol Ther* 2006; 19: 155–165.
- 129 Maes T, Provoost S, Lanckacker EA, *et al.* Mouse models to unravel the role of inhaled pollutants on allergic sensitization and airway inflammation. *Respir Res* 2010; 11: 7.
- 130 Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. *Lancet* 2009; 374: 733–743.
- 131 Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. *Eur Respir J* 2003; 21: Suppl. 41, 46s–53s.
- 132 Tam A, Churg A, Wright JL, *et al.* Sex differences in airway remodeling in a mouse model of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2016; 193: 825–834.
- 133 Gaschler GJ, Bauer CM, Zavitz CC, *et al.* Animal models of chronic obstructive pulmonary disease exacerbations. *Contrib Microbiol* 2007; 14: 126–141.
- 134 Starkey MR, Jarnicki AG, Essilfie AT, *et al.* Murine models of infectious exacerbations of airway inflammation. *Curr Opin Pharmacol* 2013; 13: 337–344.
- 135 Bauer CM, Morissette MC, Stampfli MR. The influence of cigarette smoking on viral infections: translating bench science to impact COPD pathogenesis and acute exacerbations of COPD clinically. *Chest* 2013; 143: 196–206.
- 136 Lo Sasso G, Schlage WK, Boue S, *et al.* The Apoe(-/-) mouse model: a suitable model to study cardiovascular and respiratory diseases in the context of cigarette smoke exposure and harm reduction. *J Transl Med* 2016; 14: 146.
- 137 Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. *Am J Physiol Lung Cell Mol Physiol* 2008; 294: L152–L160.
- 138 Jenkins RG, Moore BB, Chambers RC, *et al.* An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis. *Am J Respir Cell Mol Biol* 2016; 56: 667–679.
- 139 ten Have-Opbroek AA. The structural composition of the pulmonary acinus in the mouse. A scanning electron microscopical and developmental-biological analysis. *Anat Embryol* 1986; 174: 49–57.
- 140 Bruun CS, Jensen LK, Leifsson PS, *et al.* Functional characterization of a porcine emphysema model. *Lung* 2013; 191: 669–675.
- 141 Organ L, Bacci B, Koumoundouros E, *et al.* Structural and functional correlations in a large animal model of bleomycin-induced pulmonary fibrosis. *BMC Pulm Med* 2015; 15: 81.
- 142 Ostedgaard LS, Meyerholz DK, Chen JH, *et al.* The DeltaF508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs. *Sci Transl Med* 2011; 3: 74ra24.
- 143 Raju SV, Kim H, Byzek SA, *et al.* A ferret model of COPD-related chronic bronchitis. *JCI Insight* 2016; 1: e87536.
- 144 Sun X, Sui H, Fisher JT, *et al.* Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. *J Clin Invest* 2010; 120: 3149–3160.
- 145 Schwarz B, Klang A, Bezdekova B, *et al.* Equine multinodular pulmonary fibrosis (EMPF): Five case reports. *Acta Vet Hung* 2013; 61: 319–332.
- 146 Boedec K Le, Roody PJ, O'Brien RT. A case of atypical diffuse feline fibrotic lung disease. *J Feline Med Surg* 2014; 16: 858–863.
- 147 Secrest SA, Bailey MQ, Williams KJ, *et al.* Imaging diagnosis—Feline idiopathic pulmonary fibrosis. *Vet Radiol Ultrasound* 2008; 49: 47–50.
- 148 Heikkila HP, Lappalainen AK, Day MJ, *et al.* Clinical, bronchoscopic, histopathologic, diagnostic imaging, and arterial oxygenation findings in West Highland White Terriers with idiopathic pulmonary fibrosis. *J Vet Intern Med* 2011; 25: 433–439.
- 149 Miele A, Dhaliwal K, Du Toit N, *et al.* Chronic pleuropulmonary fibrosis and elastosis of aged donkeys: similarities to human pleuroparenchymal fibroelastosis. *Chest* 2014; 145: 1325–1332.
- 150 Roman J, Brown KK, Olson A, *et al.* An official American thoracic society workshop report: comparative pathobiology of fibrosing lung disorders in humans and domestic animals. *Ann Am Thorac Soc* 2013; 10: S224–S229.
- 151 Spelta CW, Axon JE, Begg A, *et al.* Equine multinodular pulmonary fibrosis in three horses in Australia. *Aust Vet J* 2013; 91: 274–280.
- 152 Williams KJ. Gammaherpesviruses and pulmonary fibrosis: evidence from humans, horses, and rodents. *Vet Pathol* 2014; 51: 372–384.
- 153 King TE Jr, Bradford WZ, Castro-Bernardini S, *et al.* A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med* 2014; 370: 2083–2092.
- 154 Myllarniemi M, Kaarteenaho R. Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. *Eur Clin Respir J* 2015; 2.

- 155 Richeldi L, du Bois RM, Raghu G, *et al.* Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med* 2014; 370: 2071–2082.
- 156 Marrie TJ. Pneumococcal pneumonia: epidemiology and clinical features. *Semin Respir Infect* 1999; 14: 227–236.
- 157 Torres A, Blasi F, Peetermans WE, *et al.* The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. *Eur J Clin Microbiol Infect Dis* 2014; 33: 1065–1079.
- 158 Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. *Thorax* 2010; 67: 71–79.
- 159 Garau J, Calbo E. Community-acquired pneumonia. *Lancet* 2008; 371: 455–458.
- 160 Chalmers JD, Taylor JK, Singanayagam A, *et al.* Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. *Clin Infect Dis* 2011; 53: 107–113.
- 161 Park IH, Pritchard DG, Cartee R, *et al.* Discovery of a new capsular serotype (6C) within serogroup 6 of *Streptococcus pneumoniae*. *J Clin Microbiol* 2007; 45: 1225–1233.
- 162 Correction: Host glycan sugar-specific pathways in *Streptococcus pneumoniae*: galactose as a key sugar in colonisation and infection. *PLoS One* 2015; 10: e0127483.
- 163 Paixao L, Oliveira J, Verissimo A, *et al.* Host glycan sugar-specific pathways in *Streptococcus pneumoniae*: galactose as a key sugar in colonisation and infection. *PLoS One* 2015; 10: e0121042.
- 164 Bischof A, Brumshagen C, Ding N, *et al.* Basophil expansion protects against invasive pneumococcal disease in mice. *J Infect Dis* 2014; 210: 14–24.
- 165 Maus UA, Backi M, Winter C, *et al.* Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection. *Am J Respir Crit Care Med* 2007; 175: 958–966.
- 166 Winter C, Herbold W, Maus R, *et al.* Important role for CC chemokine ligand 2-dependent lung mononuclear phagocyte recruitment to inhibit sepsis in mice infected with *Streptococcus pneumoniae*. *J Immunol* 2009; 182: 4931–4937.
- 167 Knippenberg S, Ueberberg B, Maus R, *et al.* *Streptococcus pneumoniae* triggers progression of pulmonary fibrosis through pneumolysin. *Thorax* 2015; 70: 636–646.
- 168 Steinwede K, Henken S, Bohling J, *et al.* TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. *J Exp Med* 2012; 209: 1937–1952.
- 169 Gutbier B, Kube SM, Reppe K, *et al.* RNAi-mediated suppression of constitutive pulmonary gene expression by small interfering RNA in mice. *Pulm Pharmacol Ther* 2010; 23: 334–344.
- 170 Lafontaine ER, Zimmerman SM, Shaffer TL, *et al.* Use of a safe, reproducible, and rapid aerosol delivery method to study infection by *Burkholderia pseudomallei* and *Burkholderia mallei* in mice. *PLoS One* 2013; 8: e76804.
- 171 Prakash H, Becker D, Bohme L, *et al.* cIAP-1 controls innate immunity to *C. pneumoniae* pulmonary infection. *PLoS One* 2009; 4: e6519.
- 172 Dames C, Akyuz L, Reppe K, *et al.* Miniaturized bronchoscopy enables unilateral investigation, application, and sampling in mice. *Am J Respir Cell Mol Biol* 2014; 51: 730–737.
- 173 Maus UA, Srivastava M, Paton JC, *et al.* Pneumolysin-induced lung injury is independent of leukocyte trafficking into the alveolar space. *J Immunol* 2004; 173: 1307–1312.
- 174 Srivastava M, Jung S, Wilhelm J, *et al.* The inflammatory versus constitutive trafficking of mononuclear phagocytes into the alveolar space of mice is associated with drastic changes in their gene expression profiles. *J Immunol* 2005; 175: 1884–1893.
- 175 Berube K, Prytherch Z, Job C, *et al.* Human primary bronchial lung cell constructs: the new respiratory models. *Toxicology* 2010; 278: 311–318.
- 176 Frija-Masson J, Martin C, Regard L, *et al.* Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis. *Eur Respir J* 2017; 49: 1601873.
- 177 Esposito AL, Clark CA, Poirier WJ. An assessment of the respiratory burst and bactericidal activity of alveolar macrophages from adult and senescent mice. *J Leukoc Biol* 1988; 43: 445–454.
- 178 Marrie TJ. Community-acquired pneumonia in the elderly. *Clin Infect Dis* 2000; 31: 1066–1078.
- 179 Alberts R, Srivastava B, Wu H, *et al.* Gene expression changes in the host response between resistant and susceptible inbred mouse strains after influenza A infection. *Microbes Infect* 2010; 12: 309–318.
- 180 De Simone M, Spagnuolo L, Lore NI, *et al.* Host genetic background influences the response to the opportunistic *Pseudomonas aeruginosa* infection altering cell-mediated immunity and bacterial replication. *PLoS One* 2014; 9: e106873.
- 181 Leepiyasakulchai C, Ignatowicz L, Pawlowski A, *et al.* Failure to recruit anti-inflammatory CD103+ dendritic cells and a diminished CD4+ Foxp3+ regulatory T cell pool in mice that display excessive lung inflammation and increased susceptibility to *Mycobacterium tuberculosis*. *Infect Immun* 2012; 80: 1128–1139.
- 182 Lore NI, Iraqi FA, Bragonzi A. Host genetic diversity influences the severity of *Pseudomonas aeruginosa* pneumonia in the Collaborative Cross mice. *BMC Genet* 2015; 16: 106.
- 183 Shin DL, Hatesuer B, Bergmann S, *et al.* Protection from severe influenza infections in mice carrying the Mx1 influenza resistance gene strongly depends on genetic background. *J Virol* 2015; 89: 9998–10009.
- 184 Srivastava B, Blazejewska P, Hessmann M, *et al.* Host genetic background strongly influences the response to influenza A virus infections. *PLoS One* 2009; 4: e4857.
- 185 Gingles NA, Alexander JE, Kadioglu A, *et al.* Role of genetic resistance in invasive pneumococcal infection: identification and study of susceptibility and resistance in inbred mouse strains. *Infect Immun* 2001; 69: 426–434.
- 186 Bleich A, Hansen AK. Time to include the gut microbiota in the hygienic standardisation of laboratory rodents. *Comp Immunol Microbiol Infect Dis* 2012; 35: 81–92.
- 187 Muller-Redetzky HC, Wienhold SM, Berg J, *et al.* Moxifloxacin is not anti-inflammatory in experimental pneumococcal pneumonia. *J Antimicrob Chemother* 2015; 70: 830–840.
- 188 Orihuela CJ, Gao G, McGee M, *et al.* Organ-specific models of *Streptococcus pneumoniae* disease. *Scand J Infect Dis* 2003; 35: 647–652.
- 189 Brown AO, Orihuela CJ. Visualization of *Streptococcus pneumoniae* within cardiac microlesions and subsequent cardiac remodeling. *J Vis Exp* 2015; 98.

- 190 Muller-Redetzky HC, Will D, Hellwig K, *et al.* Mechanical ventilation drives pneumococcal pneumonia into lung injury and sepsis in mice: protection by adrenomedullin. *Crit Care* 2014; 18: R73.
- 191 Crandon JL, Kuti JL, Nicolau DP. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant *Staphylococcus aureus* with a range of vancomycin MICs in a murine pneumonia model. *Antimicrob Agents Chemother* 2010; 54: 5115–5119.
- 192 Monogue ML, Abbo LM, Rosa R, *et al.* In vitro discordance with in vivo activity: humanized exposures of ceftazidime-avibactam, aztreonam, and tigecycline alone and in combination against new delhi metallo-beta-lactamase-producing *Klebsiella pneumoniae* in a murine lung infection model. *Antimicrob Agents Chemother* 2017; 61: e00486-17.
- 193 Force ADT, Ranieri VM, Rubenfeld GD, *et al.* Acute respiratory distress syndrome: the Berlin Definition. *JAMA* 2012; 307: 2526–2533.
- 194 Matute-Bello G, Downey G, Moore BB, *et al.* An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. *Am J Respir Cell Mol Biol* 2011; 44: 725–738.
- 195 Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. *N Engl J Med* 2000; 342: 1301–1308.
- 196 Scholten EL, Beitler JR, Prisk GK, *et al.* Treatment of ARDS with prone positioning. *Chest* 2017; 151: 215–224.
- 197 Ballard-Croft C, Wang D, Sumpster LR, *et al.* Large-animal models of acute respiratory distress syndrome. *Ann Thorac Surg* 2012; 93: 1331–1339.
- 198 Bastarache JA, Blackwell TS. Development of animal models for the acute respiratory distress syndrome. *Dis Model Mech* 2009; 2: 218–223.
- 199 Reiss LK, Uhlig U, Uhlig S. Models and mechanisms of acute lung injury caused by direct insults. *Eur J Cell Biol* 2012; 91: 590–601.
- 200 Bellani G, Laffey JG, Pham T, *et al.* Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. *JAMA* 2016; 315: 788–800.
- 201 Patel BV, Wilson MR, Takata M. Resolution of acute lung injury and inflammation: a translational mouse model. *Eur Respir J* 2012; 39: 1162–1170.
- 202 Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. *Lancet* 2007; 369: 1553–1564.
- 203 Vincent JL, Zambon M. Why do patients who have acute lung injury/acute respiratory distress syndrome die from multiple organ dysfunction syndrome? Implications for management. *Clin Chest Med* 2006; 27: 725–731.
- 204 Aeffner F, Bolon B, Davis IC. Mouse models of acute respiratory distress syndrome: a review of analytical approaches, pathologic features, and common measurements. *Toxicol Pathol* 2015; 43: 1074–1092.
- 205 Matute-Bello G, Frevert CW, Martin TR. Animal models of acute lung injury. *Am J Physiol Lung Cell Mol Physiol* 2008; 295: L379–L399.
- 206 Rosenthal C, Caronia C, Quinn C, *et al.* A comparison among animal models of acute lung injury. *Crit Care Med* 1998; 26: 912–916.
- 207 Laffey JG, Kavanagh BP. Fifty Years of Research in ARDS. Insight into ARDS - From Models to Patients. *Am J Respir Crit Care Med* 2017; 196: 18–28.
- 208 Luo L, Shaver CM, Zhao Z, *et al.* Clinical predictors of hospital mortality differ between direct and indirect ARDS. *Chest* 2017; 151: 755–763.
- 209 Tonelli AR, Zein J, Adams J, *et al.* Effects of interventions on survival in acute respiratory distress syndrome: an umbrella review of 159 published randomized trials and 29 meta-analyses. *Intensive Care Med* 2014; 40: 769–787.
- 210 Guignabert C, Tu L, Girerd B, *et al.* New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. *Chest* 2015; 147: 529–537.
- 211 Huertas A, Perros F, Tu L, *et al.* Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. *Circulation* 2014; 129: 1332–1340.
- 212 Thompson AA, Lawrie A. Targeting vascular remodeling to treat pulmonary arterial hypertension. *Trends Mol Med* 2017; 23: 31–45.
- 213 Tudor RM, Archer SL, Dorfmüller P, *et al.* Relevant issues in the pathology and pathobiology of pulmonary hypertension. *J Am Coll Cardiol* 2013; 62: Suppl. 25, D4–12.
- 214 Lawrie A. A report on the use of animal models and phenotyping methods in pulmonary hypertension research. *Pulm Circ* 2014; 4: 2–9.
- 215 Stenmark KR, Meyrick B, Galie N, *et al.* Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. *Am J Physiol Lung Cell Mol Physiol* 2009; 297: L1013–L1032.
- 216 Naeije R, Dewachter L. Chapter 5. Animal Models of Pulmonary Hypertension. In: Lynch JP, Humbert M, eds. *Pulmonary Hypertension*. Boca Raton, CRC Press 2009; pp. 59–82.
- 217 Bonnet S, Provencher S, Guignabert C, *et al.* Translating research into improved patient care in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2017; 195: 583–595.
- 218 Greenway S, van Suylen RJ, Du Marchie Sarvaas G, *et al.* S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. *Am J Pathol* 2004; 164: 253–262.
- 219 Merklinger SL, Wagner RA, Spiekerkoetter E, *et al.* Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension. *Circ Res* 2005; 97: 596–604.
- 220 Dai Z, Li M, Wharton J, *et al.* Prolyl-4 hydroxylase 2 (PHD2) deficiency in endothelial cells and hematopoietic cells induces obliterative vascular remodeling and severe pulmonary arterial hypertension in mice and humans through hypoxia-inducible factor-2alpha. *Circulation* 2016; 133: 2447–2458.
- 221 Guignabert C, Alvira CM, Alastalo TP, *et al.* Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. *Am J Physiol Lung Cell Mol Physiol* 2009; 297: L1082–L1090.
- 222 Simonneau G, Gatzoulis MA, Adatia I, *et al.* Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2013; 62: Suppl. 25, D34–D41.
- 223 Hoffmann J, Yin J, Kukucka M, *et al.* Mast cells promote lung vascular remodeling in pulmonary hypertension. *Eur Respir J* 2011; 37: 1400–1410.

- 224 Kerem A, Yin J, Kaestle SM, *et al.* Lung endothelial dysfunction in congestive heart failure: role of impaired Ca²⁺ signaling and cytoskeletal reorganization. *Circ Res* 2010; 106: 1103–1116.
- 225 Mercier O, Fadel E. Chronic thromboembolic pulmonary hypertension: animal models. *Eur Respir J* 2013; 41: 1200–1206.
- 226 Yun X, Chen Y, Yang K, *et al.* Upregulation of canonical transient receptor potential channel in the pulmonary arterial smooth muscle of a chronic thromboembolic pulmonary hypertension rat model. *Hypertens Res* 2015; 38: 821–828.
- 227 Meng Q, Lai YC, Kelly NJ, *et al.* Development of a mouse model of metabolic syndrome, pulmonary hypertension, and heart failure with preserved ejection fraction. *Am J Respir Cell Mol Biol* 2017; 56: 497–505.
- 228 Maurer B, Distler JH, Distler O. The Fra-2 transgenic mouse model of systemic sclerosis. *Vascul Pharmacol* 2013; 58: 194–201.
- 229 Yun X, Chen Y, Yang K, *et al.* Upregulation of canonical transient receptor potential channel in the pulmonary arterial smooth muscle of a chronic thromboembolic pulmonary hypertension rat model. *Hypertension Res* 2015; 38: 821–828.
- 230 Maurer B, Reich N, Juengel A, *et al.* Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. *Ann Rheum Dis* 2012; 71: 1382–1387.
- 231 Guignabert C, Phan C, Seferian A, *et al.* Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. *J Clin Invest* 2016; 126: 3207–3218.